The role of phenolic compounds in the fight against cancer – a review by Carocho, Márcio & Ferreira, Isabel C.F.R.
Send Orders for Reprints to reprints@benthamscience.net 
1236 Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1236-1258
 
The Role of Phenolic Compounds in the Fight against Cancer – A Review 
Márcio Carocho and Isabel C.F.R. Ferreira*
Mountain Research Center (ESA), Polytechnic Institute of Bragança, Apartado 1172, 5301-855 Bragança, Portugal 
Abstract: Cancer is a worldwide scourge; it’s the leading cause of death in developed countries and is increasing in developing 
countries. Mankind has been trying with effort to find better and cheaper treatments with fewer side effects, to reduce the incidence of the 
disease and its consequent mortality. For many years, phenolic compounds have been intensely studied for their antitumor, proapoptotic 
and antiangiogenic effects. In recent years, the usage of these compounds has increased considerably. 
This manuscript intends to structurally characterize the different phenolic compounds (flavonoids, hydroxycinnamates, hydroxybenzoates, 
coumarins, xanthones, chalcones, stilbenes, lignins and lignans) and their metabolic pathways as well as review the most important 
results regarding these compounds and their derivatives in cancer treatment and prevention both in tumor cell lines in vitro, in murine 
models in vivo and finally some results regarding human trials. 
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1. INTRODUCTION 
 Cancer is a worldwide burden that causes millions of deaths 
each year. In fact, it is the leading cause of death in developed 
countries, slaughtering 7.6 millions of lives in 2008. The developing 
countries have begun to register increasing cases of cancer due to 
cancer-causing behaviors like smoking and unbalanced diets. Of the 
7.6 million deaths in 2008, 64% were in developing countries [1]. 
The economic impact on the prophylaxis and treatment of this 
disease is monumental, reaching in 2002, over 60 million dollars in 
the United States alone [2]. The social and cultural implications are 
harder to calculate but also deserve a profound and adequate 
reflection as they afflict millions of citizens around the world. 
Despite the giant leap that anticancer treatments have undergone in 
the past decades it is still imperative to diminish the mortality and 
suffering of patients and reduce the costs of treatments. The world 
needs faster, more efficient and specific treatments for the different 
types of cancer, and one of the main drawbacks is drug resistance. 
This resistance may emerge from a variety of reasons, including 
alteration in the binding site of the target, metabolism and export 
mechanisms via genetic or epigenetic alterations [3]. The quest to 
find these efficient drugs is everlasting and worldwide research is 
growing every day. 
 Since ancient times, plants have been used as remedies to  
treat different types of illnesses and lesions with satisfying  
results. Today, more than 60% of anticancer drugs come from 
natural compounds or are derived from them, making these 
bioactive molecules become increasingly interesting for drug 
companies, even as prototypes of final formulations for anticancer 
drugs [4, 5]. It is known that plant extracts can display interesting 
anticancer effects on cell lines and murine models, yielding higher 
effects when compared to pure natural or synthetic compounds. 
Despite this remarkable effect, it is difficult to assess which 
compounds are interacting with the cancer cells or if this 
orchestrated effect is due to synergy between various compounds. 
Another disadvantage of extracts is the difficulty to obtain enough 
quantity of plants to produce them, while the natural compounds 
can, in some cases, be synthesized in a laboratory, reducing the 
need for intense gathering. 
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2. SECONDARY METABOLITES
 For 200 years, modern chemistry has managed to describe the 
functions of plant primary metabolites as being related to basic 
functions like cell division and growth, respiration, storage and 
reproduction. These metabolites comprehend phytosterols, acyl 
lipids, nucleotides, amino acids and organic acids. Secondary 
metabolites tend to accumulate in plant tissues; they play an 
important role in the plants adaptation process, acting as antibiotics, 
antifungals, antivirals, UV absorbing agents to reduce damage to 
tissues, signal molecules, allelopathic agents, attractants for 
pollinators and seed-dispersing animals as well as protecting the 
plant against herbivores. For mankind, these metabolites are also 
important for providing dyes, fibers, glues, oils, waxes, flavoring 
agents, perfumes, insecticides, herbicides and are sources of new 
natural drugs for many diseases [6, 7]. The secondary metabolites 
are usually classified through their biosynthetic pathways, and are 
divided into three large families: alkaloids, terpenes and steroids, 
and phenolic compounds [6]. They are mainly found in storage 
tissues rather than in vegetative ones, due to their high biologic 
potency [8].  
2.1. Terpenes and Steroids
 Terpenes and steroids are known for their lipophilic properties 
and their biosynthetic origin through the mevalonate and 
mevalonate-independent pathways. In terms of structure, they are 
unsaturated cyclic or linear hydrocarbons with varying degrees  
of oxygenation. They are subdivided according to the number  
of five carbon units (isoprene) which are the building blocks  
of these compounds. It is now known that isoprene occurs naturally 
but is not involved in the formation of these compounds, rather  
by isomers of isopentenyl pyrophosphate and dimethylallyl 
pyrophosphate. Terpenes may vary from monoterpenoids (C10) to 
tertraterpenoids (C40), which are forty carbon molecules. Steroids 
are modified triterpenoids (C30) and derive from squalene which  
is transformed into lanosterol. The basic structure of steroids  
is the well-known cholesterol molecule, with the typicall four  
fused cycloalkane rings. Substitutions in the functional groups 
surrounding the nucleus which is formed by the fused rings, confer 
a high metabolic activity to steroids, allowing them to be used as 
hormones, drugs and anti-inflammatory medication [7-11]. 
2.2. Alkaloids
 The alkaloids are a diverse group of low molecular weight, 
nitrogen-containing compounds. They also play a defensive role in 
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plants, defending them from herbivores and pathogens. As many as 
12000 alkaloids have been used as pharmaceuticals, stimulants, 
narcotics and poisons since the first alkaloid, morphine, was 
discovered [7]. Not all alkaloids derive from amino acids and, 
allowing a division into four groups: a) alkaloids derived from 
amino acids (ornithine, arginine, lysine, histidine, phenylalanine/ 
tyrosine, tryptophan, anthranilic acid and nicotinic acid); b) purine 
alkaloids (xanthine and caffeine); c) aminated terpenes (diterpene 
aconitine, triterpene solanine); e) polyketide alkaloids (consisting of 
nitrogen introduced into a polyketide carbon skeleton) [12].  
2.3. Phenolic Compounds
 Phenolic compounds are widely dispersed throughout the plant 
kingdom representing about 8000 different phenolic structures. As 
secondary metabolites they also display defensive, growth and 
development effects. They have at least one aromatic ring with one 
or more hydroxyl groups attached, being able to range from low 
molecular weight molecules to large and complex ones. The 
biosynthesis of phenolic compounds involves the shikimate, 
phenilpropanoid and flavonoid pathways [7, 13]. Phenolic 
compounds generally appear as esters and glycosides rather than as 
free compounds due to the conferred stability of these molecules. 
This family of compounds is one of the most studied worldwide and 
innumerous publications report beneficial effects in various aspects 
of human health and well-being [13-15]. Fig. (1) represents the 
various groups of molecules within the phenolic compounds family, 
while Table 1 displays their structure as well as the number of 
carbons and representative compounds.
2.3.1 Hydroxybenzoic Acids
 Regarding the Hydroxybenzoic acids group, they are composed 
of seven carbon molecules with a C6-C1 skeleton and are produced 
through the shikimate pathway. These compounds are universally 
distributed in the plant kingdom, being gallic, protocatechuic, 
vanillic, and syringic acids the four most abundant compounds. 
Within this group of compounds there is a sub-group, the tannins, 
which vary greatly from small molecules to large ones. There are 
two categories of tannins, the hydrolysable and the non-
hydrolysable or condensed tannins. The hydrolysable tannins have a 
central core of polyhydric alcohol such as glucose and hydroxyl 
groups which can be esterified by gallic acid, while condensed 
tannins are structurally more complex and are the result of 
polymerization by some flavonoids [7, 10, 16, 17].
2.3.2. Hydroxycinammic Acids
 The Hydroxycinnamic acids represent a group of compounds 
that derive from cinnamic acid through the phenilpropanoid 
pathway. They display a C6-C3 skeleton of trans-phenyl-3-
propenoic acid with one or more hydroxyl groups attached to the 
phenyl moiety, some of which may be methylated. The precursors 
of this group of compounds are the aminoacids L-phenylalanine and 
L-tyrosine. Hydroxycinammic acids display a defensive and UV 
protective effect in plant models. The most abundant compounds 
within this group are p-coumaric, caffeic and ferulic acids [7, 10, 
18, 19]. 
2.3.3. Coumarins
 Coumarins derive from phenolic acids and display a benzene 
ring fused to an oxygen heterocycle. The four most common 
coumarins are coumarin, umbelliferone, esculetin and scopoletin 
among the 1000 naturally occurring ones in higher plants. Free 
coumarins can be found in plants, but most of the simple ones are 
usually glycated. The major quantities of coumarins are found in 
roots and seeds, but have also been described in all the different 
organs of plants [20, 21]. 
2.3.4. Xanthones
 These compounds occur mostly in higher plant families, namely 
in the Gentianaceae, Guttiferae, Polygalaceae, Leguminosae, 
Lythraceae, Moraceae, Loganiaceae, and Rhamnaceae. Structurally 
they are comprised of heterocyclic compounds, quite similar to 
flavonoids, with a C6-C1-C6 skeleton. Xanthones are usually 
classified in 5 major groups: Simple oxygenated xanthones, xanthone 
glycosides, prenylated and related xanthones, xanthonolignoids and 
miscellaneous. Their in vitro and in vivo antitumor potential has 
recently been object of a considerable numbert of studies [22].
2.3.5. Chalcones
 Chalcones display a C6-C3-C6 skeleton without a heterocyclic 
C-ring and are intermediates in the formation of all flavonoids. 
They have an open chain conformation with two aromatic rings 
joined by a three-carbon ,- unsaturated carbonyl system. Most 
chalcones are yellow colored and occur mostly in flowers, but can 
be found in other plant organs. Some occur as glycosides, although 
most of them are found as free aglycones. They have been reported 
to have antioxidant, anti-fungal and anti-cancer properties [21, 23].
2.3.6. Stilbenes
 The members of the stilbene family exhibit a C6-C2-C6 
structure and derive from the same biosynthetic pathway as 
flavonoids. Although small, these compounds are widely distributed 
throughout the plant kingdom. There are over 200 stilbenes and 
stilbene glycones reported in higher plants. The most important 
stilbene is resveratrol, which has been extensively studied in recet 
years due to its antitumor potential [7, 21].
Fig. (1). Molecular groups of the phenolic compounds family. 
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2.3.7. Lignins
 Lignin is a polymer with many branches, composed of three 
simple alcohols known as monolignols. There are three major 
groups of lignins: lignins of softwoods (gymnosperms), lignins of 
hardwoods (angiosperms) and lignins of grasses (non-woody or 
herbaceous plants). It is the third most abundant polymer in nature, 
topping 300 billion metric tons on Earth. In plant tissues, lignin is 
bonded to other polymers like cellulose and hemicellulose. 
Antioxidant, anti-hypertensive and anticancer properties have been 
described in lignins, lignin derivatives and in complexes formed 
with them [24-27]. 
2.3.8. Lignans
 Lignans are the result of the union of two cinnamic acid 
residues or their biogenic relatives. They are distributed throughout 
the plant kingdom in many vascular plant families, being present in 
all their organs. These compounds are also known for their 
beneficial effects, namely anticancer, antioxidant, hepatoprotective 
and antiviral [28, 29].
2.3.9. Flavonoids
 The flavonoids are the most numerous group of molecules 
within the phenolic compounds and are widespread through the 
plant kingdom. They are polyphenolic compounds that derive from 
chalcones and display an arrangement of three aromatic rings (A, B 
and C) with fifteen carbons and a C6-C3-C6 skeleton which can 
have innumerous substituents. The A ring is a benzene, condensed 
with a six-member ring (C), which carries a phenyl benzene in 
position 2 (ring B) as a substituent. Ring C can be a heterocyclic 
pyran (Table 2). Flavonoids have a mixed biosynthesis, and are 
products of both the shikimate and acetate pathways. They 
accumulate mainly in the epidermis of leaves and skin of fruits, and 
are involved in UV protection, pigmentation, disease resistance and 
stimulation of nitrogen fixing. Sugars, in the form of glycosides are 
normally joined with flavonoids and while they increase water 
solubility along with hydroxyl groups, other substituents like 
methyl groups and isopentenyl units increase their lipophilic 
properties. The main subclasses of flavonoids are flavonols, 
Table 2. Representation of the basic structures of the flavonoid 
subclass.
Table 1. Classification through number of carbons and basic structure of molecules within the phenolic compounds family.
Number of Carbons Classification Example Basic Structure
7 Hydroxybenzoic acids Gallic acid
OH
O
9 Hydroxycinnamic acids p-coumaric acid
O
OH
9 Coumarins Esculetin
O O
13 Xanthones Mangiferin
O
O
14 Stilbenes Resveratrol
15 Flavonoids Naringenin O
Table 2. Representation of the basic structures of the flavonoid 
subclass.
Classification Examples Basic Structure
Flavonol
Quercetin
Kaempferol
Myricetin
O
O
OH
Flavone
Apigenin
Chrysin
O
O
Flavanol Catechin O
OH
Isoflavone Genistein
O
O
Flavanone Hesperidin
O
O
Anthocyanin
Pelargonidin
Cyanidin
O
+
OH
The Role of Phenolic Compounds in the Fight against Cancer – A Review Anti-Cancer Agents in Medicinal Chemistry, 2013, Vol. 13, No. 8    1239 
flavones, flavanols or flavan-3-ols, isoflavones, flavanones and 
anthocyanidins [7, 10, 30-32]. Table 2 represents the basic structure 
and some examples of all these subclasses.
2.3.9.1. Flavonols
 Flavonols are considered, not without debate, the most 
widespread flavonoids throughout the plant kingdom, and 
considered, along with flavones, the major subclass of flavonoids. 
The most abundant compounds within the flavonols are myricetin, 
quercetin and kaempferol that tend to occur as O-glycosides. 
Conjugation usually occurs at the third carbon of the C-ring, 
although conjugations have also been found at positions 5, 7, 4’, 3’ 
and 5’. It is estimated that in Western countries the daily intake of 
flavonols is between 20 to 50 mg, and although these compounds 
are found in many fruits and vegetables, considerable quantity 
differences may be found between the same species, due to seasonal 
changes, varietal and edaphoclimatic variations. The benefits of 
flavonols consumption are related to protection against athero- 
sclerosis, osteoporosis, diabetes mellitus and certain cancers [7, 32, 33]. 
2.3.9.2. Flavones
 The flavones are structurally related to flavonols and are also 
considered a major subclass within the flavonoids; they occur 
usually as 7-O-glycosides, although other substitutions can be 
found. These compounds derive directly from flavanones, by 
abstraction of two hydrogen atoms and introduction of a double 
bond between carbons 2 and 3. Flavones seem to have protective 
and communication roles in plants, protecting against UV radiation 
and interacting with microbes, insects and other plants. The most 
common compounds within the flavones are apigenin, chrysin and 
luteolin. The main benefits to human health from flavones are 
antioxidant, anticarcinogenic, antiviral, anti-inflammatory and 
antiatherosclerotic [7, 34]. 
2.3.9.3. Flavanols
 The flavanols or flavan-3-ols are the most complex subclass of 
flavonoids; they encompass simple molecules like catechin and 
large polymeric proanthocyanidins. This subclass of flavonoids, 
unlike the others is not planar due to a saturated C3 element in the 
heterocyclic C-ring. In plant systems, the flavanols act against 
harmful intruders like microbes, insects and herbivores; they also 
have the ability to chelate metals and to confer resistance to high 
lead levels. In food, flavanols are responsible for astringency, 
bitterness, sourness, salivary viscosity, aroma and color formation. 
The average daily consumption of flavanols in the United States 
was 57.7 mg/person in between 2004 and 2005. Once inside the 
body, these compounds have shown antioxidant, anticarcinogen, 
antiviral and neuroprotective effects [7, 35]. 
2.3.9.4. Isoflavones
 The isoflavones, also known as phytoestrogen compounds due 
to their phytoestrogenic activity, differ from other subclasses within 
the flavonoids class by having the B-ring attached to the C3 carbon 
rather than the C2. Isoflavones are only found in leguminous plants, 
being soybeans the highest producer. The main representatives of 
the isoflavones are genistein and daidzein along with their 
respective acetyl, malonyl and aglycone forms. Isoflavones have 
been reported to have antitumor activity along with antioxidant and 
antiviral potential, although some data is controversial [7, 36-38]. 
2.3.9.5. Flavanones
 The flavanones are usually considered a minor subclass within 
the flavonoids due to their limited occurrence, mainly in fruits and 
especially in citrus. They are characterized by the absence of a 
double bond and a chiral center in the C ring. Chalcones are usually 
incorporated into this subclass due to being similar to flavanones; 
the main difference is the open C ring in chalcones, and the 
possibility of conversion of flavanones into chalcones in alkaline 
media and vice-versa in acidic environments. Examples of 
flavanones are hesperidin (orange juice) and naringine (grapefruit) 
and due to the high levels of hesperidin in orange juice, it has a sour 
taste, while naringine is sweeter. Flavanones have also been 
reported to have anticancer properties and effective in preventing 
cardiovascular diseases [7, 39-41].
2.3.9.6. Anthocyanidins
 Anthocyanidins, also known as condensed tannins are present 
throughout the plant kingdom, especially in their glycated forms; 
the anthocyanins are found in fruits and flowers in a higher 
quantity, but also in leaves, stems and roots. These molecules are 
responsible for conferring red, blue and purple colors in plants as 
well protecting them from excessive light and attracting pollinators. 
The most abundant anthocyanidins are pelargonidin, cyaniding, 
delphinidin and peonidin. Conjugation with other molecules can 
take place in positions 3, 5, 7, 3’ and 5’, creating bigger molecules. 
In terms of human health, anthocyanins have been reported to have 
anti-inflammatory potential, DNA protection and regulator of 
immune responses [7, 42-45]. 
3. CANCER MECHANISMS
 Cancer may have various endogenous causes (e.g. inherited 
mutations, hormones, and immune conditions) which are inevitable, 
but also exogenous ones, like tobacco consumption, diet related, 
radiation, and infectious organisms. The close link between cancer 
and oxidative stress, arising from various sources, gives way to 
some debate within the scientific community due to the role of 
prooxidants. While some scientists point them as potentially 
carcinogenic, others disagree and appoint out their benneficial 
mitigating effect on certain types of cancer [46]. Despite this 
controversy, prooxidants are known to be involved in 
carcinogenesis. According to Anand et al. [47], whom reviewed the 
literature and stated that “cancer is a preventable disease that 
requires major lifestyle changes”, only 5 to 10% of cancers were 
caused by genetic defects and the remaining 90 to 95% were due to 
environment and lifestyle. This could be a promising premise, but, 
attending to the current number of smokers worldwide, the 
nutritional imbalanced diets of developed and developing countries 
and the wrong behaviors regarding Sun exposure, the cases of 
cancer are estimated to grow. In fact, considering that by 2050, 27 
million new cancer cases and 17.5 million deaths are estimated to 
occur [48] it is imperative to understand cancer mechanisms in 
order to intervene with the right methodologies.
 Meng et al. [49] reviewed the major theories that lead to cancer, 
available since the beginning of the century, and divided them into 
8 categories:
• Cancer caused by viruses 
• Chromosomal abnormalities 
• Somatic mutations 
• Accumulated multiple mutations 
• Immunological surveillances 
• Nonhealing wounds 
• Nonmutagenic mechanisms 
• Tissue organization field theories 
 Regarding cancer caused by viruses, when Francis Peyton Rous 
claimed in 1911 that cancer could be induced by a virus, the 
scientific community discredited his work, and only 50 years later 
was hiswork recognized with a Nobel Prize of Physiology or 
Medicine. Today, it is widely known that viruses like Epstein-Barr, 
Hepatitis B, Human T-cell lymphototropic type 1, Papillomavirus, 
Hepatitis C, Kaposi’s sarcoma-associated herpesvirus and Merkel 
cell polyomavirus can induce carcinogenesis. Although some 
oncogenic viruses are common among humans, not all infections 
lead to cancer. The biggest setback in this field is the multitude of 
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mechanisms used by each virus to induce cancer, but the scientific 
community is also using them to counter-attack [50-52]. 
 In terms of chromosomal abnormalities, many tumors have the 
same genesis, either by nonrandom deletion or aberration of 
specific parts of chromosomes. In 2000 more than 600 recurrent 
balanced chromosome rearrangements had been identified [53, 54]. 
 It is known that changes in the immune system, hormonal 
status, gene expression, and signaling between tissues have a key 
role in terms of probability and timing of cancer progression, but 
somatic mutation is the only process that determines progression of 
tissues at all ages, explaining the variation in age of cancer 
incidence. The somatic mutation theory premises are: 1) cancer is 
derived from a single somatic cell that has accumulated multiple 
DNA mutations; 2) the default state of cell proliferation in metazoa 
is quiescence; 3) cancer is a disease in cell proliferation caused by 
mutations in genes that control proliferation and the cell cycle. The 
sporadic cancers that derive from somatic mutation represent 95% 
of all cancers, and are some of the most researched throughout the 
world. It is now generally accepted that most tumors don’t 
perpetuate themselves with only one mutation; many mutated 
chromosomes have been found in tumors and the rate and 
complexity of the mutations dictate the speed and danger of each 
type of cancer [55-57]. 
 Immunological surveillance was first hypothesized by Burnet 
and Thomas [58, 59], back in 1959, postulating that the immune 
system can recognize and destroy nascent transformed cells. After 
being abandoned, this theory regained prominence in 1990, when 
the usage of animal models confirmed a cancer immunoediting 
mechanism. There are three essential phases: 1) elimination; 2) 
equilibrium and 3) escape. Initially, nascent transformed cells are 
eliminated by immune effector cells as part of an innate response. 
In the equilibrium stage, the elimination of the transformed cells 
sculpts the immune system inducing tumor variants decreasing 
immunogenicity and becoming resistant to effector cells. Finally in 
the escape phase, tumor-derived factors induce several escapes 
from immune attack, therefore promoting the tumor growth [60, 
61]. 
 The theory that cancer could be related with wound healing 
started with Alexander Haddow and, short after, Harold Dvorak, 
whom described cancer as a nonhealing wound. Today, it is known 
that wound healing shares common features with tumor genesis; in 
fact, both tissue regeneration and tumorigenesis involve cell 
proliferation, survival and migration, which are controlled by 
growth factors and cytokines as well as inflammatory and 
angiogenic signals. Understanding the similarities between wounds 
and the development of cancer as well as the wrong healing patters 
may help understand the uncontrolled growth of tumors [62-64].
 The nonmutagenic mechanisms of carcinogenesis are based on 
the fact that the development of a tumor might not be due to 
mutations or aberrations in the DNA, but to mitogens and cytotoxic 
carcinogens. Regarding mitogens, these can cause increased cell 
replication without displaying any cytotoxicity by interacting 
directly with cell receptors. A result of this uncontrolled replication 
is pleiotropic responses like enzyme induction, cytomegaly and 
peroxisome proliferation. On the other hand, cytotoxic carcinogens 
induce histopathological lesions, necrosis and the release of specific 
enzymes into the serum. Cell proliferation resulting of cytotoxic 
compounds replaces the cells that are damaged after this 
aggression, and may stimulate growth of spontaneously occurring 
preneoplastic cells. This increased cell division may also induce 
genetic damage by increasing the number of genetic errors due to 
rapid cell division and reduced time for accurate DNA repair [65, 
66]. 
 Finally, the organization field theory is based on the hypothesis 
that carcinogenesis is a problem of tissue organization and that 
proliferation is the default state of all cells. The underlying 
mechanism of this theory states that carcinogens disrupt the normal 
interactions between cells in the stroma and parenchyma of a given 
organ. This disruption would reduce the cell’s understanding of its 
positional and historical background. The alteration of the stroma-
epithelium would result in a hyperplastic state. The last step in this 
hypothesis would be the modification of the tissue pattern that 
could result in dyplasia or even in metaplasia [67, 68]. 
 All cancer theories have limitations and fail to explain 
thoroughly certain types of cancer as well as the underlying 
mechanisms behind them. While some research groups look deeper 
into the genesis of a tumor, others venture into how natural or 
synthetic compounds can destroy the tumor. 
4. FIGHTING CANCER WITH PHENOLIC COMPOUNDS
 In 2003, when the complete human genome was sequenced, 
many scientists throughout the world considered it a landmark for 
the future treatment of genetic and non-genetic diseases [69]. 
Although many advances have been made, natural compounds did 
not lose their influence, in fact, between 1981 and 2006, 47.1% of 
the 155 clinically approved anti-cancer drugs, were unmodified 
natural products or their semi-synthetic derivatives or even 
synthesized molecules based on natural models. 
 Some of the biggest contributions in terms of pure molecules 
come from the secondary metabolites of plants, namely 
polyphenols, and have had important roles both “in vitro” and “in 
vivo”: 
4.1. Hydroxybenzoic Acids
 The most studied compounds in this group are gallic, ellagic 
and ferulic acids (Table 3). In terms of “in vitro” chemotherapeutic 
assays, in 2007, Madlener et al. [70] used gallic acid in leukemic 
cell lines and reported an inhibition of ribonucleotide reductase 
(enzyme that catalyzes the formation of deoxyribonucleotides from 
ribonucleotides) activity in tumor cells, resulting in a halt to tumor 
growth. Early and late apoptosis was dependent on the 
concentration of gallic acid. In another study regarding leukemia, 
gallic acid induced apoptosis by inhibiting BCR/ABL kinase (an 
oncogene), NF-kB (protein complex that is responsible for DNA 
transcription) and COX-2 (enzyme involved in cancer expression 
by promoting cell division and inhibiting apoptosis) [71]. This acid 
also proved to be effective against glioma cell lines in a dose 
dependent manner. Moreover it had a selective cytotoxicity to the 
glioma cells when compared to sane brain cells and decreased cell 
viability, proliferation and reduced angiogenesis [72]. Gallic acid 
also had remarkable effects on lung cancer cell lines by inducing 
apoptosis and activating caspases (apoptotic enzymes). In murine 
models, gallic acid seemed to reduce the rate of tumor gowth [73]. 
Regarding ellagic acid, a study carried out in 2011, used this 
compound against murine colon cancer and reported some 
interesting results; the mice were inoculated with 1,2-dimethyl 
hydrazine (carcinogenic inducing compound) for 15 weeks and then 
treated with ellagic acid for the following 15. This hydroxybenzoic 
acid prevented the activation of PI3K/Akt pathway (associated with 
colon carcinogenesis) which down regulated Bcl-2 proteins 
(apoptosis regulator proteins), increased Bax levels (pro-apoptotic 
protein) and activated caspase-3. Finally, this cascade of events 
resulted in elevation of cytochrome c and consequent apoptosis of 
the cancer cells [74]. Ellagic acid also seems to be promising for 
local chemotherapy. Kim et al. [75] used a chitosan/ellagic acid 
composite implanted subcutaneously in rats with glioma and 
reported angiogenesis suppressing capabilities as well as apoptosis 
in an ellagic acid concentration-dependent manner. 
 Ferulic acid seems to have some type of chemopreventive effect 
when administered orally, both in skin and mammary murine 
cancers by preventing the formation of these tumors. Although the 
mechanisms of this effect are not fully understood, the results are 
promising [76, 77]. 
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 Tannins, a sub-class of hydroxybenzoic acids also manifest 
some antitumoral activity. Cuphiin D1, an hydrolysable tannin 
proved to have some apoptotic properties against leukemia cell 
lines [78], another tannin, oenothein B, proved to be effective 
against mammary carcinoma and fibrosarcoma in murine models by 
activating macrophages [79]. Wang et al. [80] carried out a study 
with four tannis extracted from Cuphea hyssopifolia. They tested 
cuphiin D1, cuphiin D2, oenothein B and woodfordin C against 
human oral epidermoid carcinoma, human promyelocytic leukemia, 
human hepatocellular carcinoma, human prostate carcinoma, 
human cervical carcinoma and mouse sarcoma cell lines. 
Surprisingly, all the tested tannins inhibited the growth of the 
tumors and revealed lower cytotoxicity than Adriamycin (a 
commercially available antibiotic used in certain types of cancer) in 
a normal cell line. Moreover, these tannins also inhibited the 
viability of sarcoma tumor cell lines as well as in vivo mice models.
4.2. Hydroxycinnamic Acids
 One of the most important compounds within the 
hydroxycinammic acids is caffeic acid which displays some 
anticancer activities (Table 4). Chen et al. [81] used its derivative, 
caffeic acid phenethyl ester (CAPE) in human leukemic cell lines 
and reported an arrest on the tumor growth. At the time, the authors 
didn’t understand the mechanisms leading to the activity. Two 
decades afterwards, Kuo et al. [82] used the same caffeic acid 
derivative on human glioma cell lines, and described an inhibition 
of growth of the cells by decreasing the hyperphosphorylation of 
the protein retinoblastoma, that when in this state is incapable of 
suppressing tumors. Furthermore, they found that CAPE up-
regulates cyclin dependent kinase inhibitors p16, p21 and p27. 
After this preliminary assay, murine xenografts were attempted and 
proved that CAPE decreased the size of tumors in a dose dependent 
manner by reducing the number of mitotic cells and proliferating 
cell nuclear antigen positive cells. Other authors have also proved 
the excellent results of CAPE against glioma cell lines, by 
inactivating DNA and arresting the cell cycle of the tumor cells [83, 
84]. Cinnamic acid also displays an antitumor activity, namely 
against colon adenocarcinoma by antiproliferative methods like 
enzyme induction and modulation of the cAMP signaling pathway 
[85]. Cinnamic acid derivatives, drupanin and baccharin, inhibits 
the growth of HeLa-60 cell lines by inducing apoptosis [86]. 
Panobinostat, is an anticancer drug that derives from the 
hydroxycinnamic acid group and acts by inhibiting histone 
deacetylase, which intervenes in carcinogenic pathways [87, 88]. 
Despite already being commercialized, hepatic clinical studies are 
still being carried out to access its efficacy [89]. 
Table 3. Hydroxybenzoic acids and related compounds with reported antitumor activity.
Compound Type of Tumor Type of Assay Result Summary Reference
Leukemia In vitro human cell lines
Ribonucleotide reductase inhibition
Apoptosis [70]
Glioma In vitro human In vitro murine cell lines Cell viability, proliferation and angiogenesis decrease [72]Gallic acid
Lung carcinoma
In vitro human cell lines 
In vivo murine models
Apoptosis and DNA damage
Activation of caspases
Tumor inhibition in vivo
[73]
Colon carcinoma In vivo murine models
Prevention of Pl3k/Akt activation
Bax expression and caspases-3 activation leading to 
apoptosis
[74]
Ellagic acid
Glioma In vivo murine models
Angiogenesis suppressing
Apoptosis [75]
Skin carcinoma In vivo murine models Prevention of tumor formation [76]
Ferulic acid
Mammary carcinoma In vivo murine models Prevention of tumor formation [77]
Cuphiin D1 
(tannin)
Leukemia
Epidermoid carcinoma
Hepatocellular carcinoma 
Prostate carcinoma Cervical 
carcinoma Murine sarcoma-180
In vitro human cell lines
In vitro murine cell lines
Apoptotic properties
Tumor inhibition
[80]
[78]
Oenothein B 
(tannin)
Mammary carcinoma
Fibrosarcoma
Leukemia
Epidermoid carcinoma
Hepatocellular carcinoma
Prostate carcinoma Cervical 
carcinoma Murine sarcoma-180
In vivo
murine models
In vitro human cell lines
In vitro murine cell lines
Macrophages activation
Tumor inhibition
[79]
[78]
Cuphiin D2
Mammary carcinoma
Fibrosarcoma
Leukemia
Epidermoid carcinoma
Hepatocellular carcinoma 
Prostate carcinoma Cervical 
carcinoma Murine sarcoma-180
In vivo
murine models
In vitro human cell lines 
 In vitro murine cell lines
Macrophages activation
Tumor inhibition [78]
Woodfordin C
Mammary carcinoma
Fibrosarcoma
Leukemia
Epidermoid carcinoma
Hepatocellular carcinoma
 Prostate carcinoma Cervical 
carcinoma Murine sarcoma-180
In vivo
murine models
In vitro human cell lines
In vitro murine cell lines
Macrophages activation
Tumor inhibition [78]
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4.3. Coumarins
 Coumarins represent a group of compounds that have been 
described as having antitumoral activity to a certain extent. Within 
this group, compounds such as coumarin, 4-hydroxycoumarin, 7-
hydroxycoumarin, psoralidin, warfarin, dicoumarol, daphetin  
and aesculetin, as well as complexes with other compounds,  
have been studied for anticancer properties (Table 5). In terms of  
in vitro studies, coumarin and its derivatives, along with 7-
hydroxycoumarin, had activity against human pancreatic [90] and 
lung [91] cancer cell lines. Jung et al. [92] synthesized 4-
hydroxycoumarin derivatives and tested them against various 
human cancer cell lines (lung, ovarian, melanoma, brain and  
colon), postulating that three of these derivatives had satisfactory 
anticancer effects against the cell lines and one of them had 
excellent results. Psoralidin is known to have an antitumor effect by 
inducing TRAIL-mediated apoptosis in cervical cancer. TRAIL is 
an apoptosis-inducing ligand of the TNF superfamily [93]. 
Daphetin seemed to exhibit anticancer results against renal 
carcinoma cells by activating p38 and inhibiting S phase of the cell 
cycle, but did not promote apoptosis [94]. Dicoumarol, another 
compound from the coumarin family doesn’t seem to inhibit cancer 
cell lines, but in turn enhances the activity of anticancer drugs like 
cisplatin [95] and doxorubicin [96]. Aesculetin has also 
demonstrated apoptotic activity against cervical cancer cell lines 
[97]. Complexes between coumarins and other molecules are also 
prone to inhibit cancer cell lines in vitro. Thati et al. [98], 
demonstrated that a complex between copper-coumarin-dioxyacetic 
acetate-phenathroline ([Cu(cdoa)(phen)2]) against kidney 
adenocarcinoma and hepatocellular carcinoma displayed 
satisfactory antiproliferative effect, especially for the liver cancer 
cell lines. Not many in vivo studies have been reported regarding 
coumarins, although the in vitro studies have opened the 
opportunity for this. Lake [99] reviewed coumarin metabolism, 
toxicity and carcinogenicity in rodents and humans and postulated 
that although this compound could induce cancer in rodents it was 
safe to be consumed by humans due to an excretion metabolic 
pathway present in humans that is a minor one in rodents, 
generating toxicity to them. Moreover, he reviewed the anticancer 
in vivo studies and reported that coumarin inhibited forestomach 
and mammary cancer in mice as well as spontaneous tumors in 
transgenic mice. Finally, he also reviewed the clinical trials that  
this compound was involved in, and concluded that the side effects 
were mild and hepatotoxicity was reverted after the treatment  
with coumarin was terminated. Marshall et al. [100], reported  
that coumarin had a stationary effect in 12 of 45 patients  
with metastic renal cell carcinoma, while Nolte et al. [101]  
reported that the combined treatment of coumarin and cimetidine 
(histamine H2 receptor antagonist) had no effect on 17 patients with 
advanced malignant melanoma. Recently, a study published on 
clinicaltrials.gov reported that the combined treatment of the 
coumarin warfarin with vatalanib, could help patients with 
advanced solid tumors. While the kinase inhibitor vatalanib stopped 
Table 4. Hydroxycinnamic acids and related compounds with reported antitumor activity.
Compound Type of Tumor Type of Assay Result Summary Reference
Leukemia In vitro human cell lines Oncogene suppression and tumor inhibition [81]
Glioma
In vitro murine cell lines
In vivo murine xenografts
Hyperphosphorylation decrease of retinoblastoma
Up-regulation of kinase inhibitors p21, p27 and p16
[82]
Caffeic acid phenethyl 
ester
Glioma In vitro murine cell lines p38 MAPK mediation of CAPE-induced p53-dependent apoptosis [83]
Glioma
In vitro murine cell lines
In vivo murine xenografts
Inhibition of motility
Induction of tumor suppressor RhoB
Metastasis inhibition
[84]
Cinnamic acid
Colon adenocarcinoma In vitro human cell lines
Enzyme induction
Modulation of cAMP signaling pathway
[85]
Cinnamic acid derivatives Cervical carcinoma In vitro human cell lines Apoptosis [86]
Table 5. Coumarins and related compounds with reported antitumor activity.
Compound Type of Tumor Type of Assay Result Summary Reference
Coumarin derivatives Pancreatic cancer In vitro human cell lines Cytotoxicity to cancer cells [90]
Courmarin
7-hydroxycoumarin Lung carcinoma In vitro human cell lines
Inhibition of cell proliferation
Apoptosis induction [91]
4-hydroxycoumarin derivatives
Lung carcinoma Ovarian carcinoma Melanoma
Brain carcinoma
Colon carcinoma
In vitro human cell lines Cytotoxicity to cancer cells [92]
Psoralidin Cervical carcinoma In vitro human cell lines TRAIL mediated apoptosis [93]
Daphetin Renal carcinoma In vitro human cell lines
Activation o p38
Cell cycle arrest [94]
Dicoumarol
Bladder carcinoma
Prostate carcinoma In vitro human cell lines Enhancement of anticancer drugs
[95]
[96]
Aesculetin Cervical carcinoma In vitro human cell lines ROS mediated apoptosis [97]
Copper-coumarin-dioxyacetic 
acetate-phenathroline complex
Kidney adenocarcinoma
Hepatocellular adenocarcinoma In vitro human cell lines Antiproliferative effect [98]
Coumarin Renal carcinoma Epidemiological studies Enhancement of anticancer drug [100]
Warfarin Solid tumors Epidemiological studies Side effect of anticancer drug reduction [102]
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the tumor growth by inhibiting angiogenesis, warfarin prevented the 
formation of blood clots [102].  
4.4. Xanthones
 Xanthones are a small group of compounds that have also 
proven interesting as natural anticancer molecules. The most 
notorious origin of xanthones is the fruit of the purpule magosteen 
(Garcinia mangostana), yielding a number of xanthones, especially 
-, - and -mangostin which are also the most studied compounds 
of this group (Table 6). These three compounds have been described 
as in vitro chemopreventive and chemotherapeutic agents against, 
colon carcinoma [103-105], leukemia [106], melanoma [107], neck 
carcinoma [108], glioblastoma [109] and others [110]. Ho et al.
[111] investigated the in vitro activity of 6 xanthones against 14 cell 
lines, and postulated that garcinone E was the best compound 
among the studied by inducing apoptosis in hepatoma, gastric and 
lung cancer cells proving to be more potent than commercial 
anticancer drugs. Other xanthones have also been investigated to a 
lesser extent against cholangiocarcinoma. These compounds, 
isomorellin, isomorellinol, forbesione and gambogic acid inhibited 
growth of those cancer cells in a dose dependent manner, being 
isomorellinol the most potent compound [112]. Although this group 
of polyphenols seems to have promising molecules with regard to 
in vitro assays, virtually no record of in vivo or clinical trials is 
reported against cancer. This might be due to a poor understanding 
of the mechanism of action of xanthones, which should be 
investigated thoroughly [113].  
4.5. Chalcones
 Chalcones are a family of polyphenols with a wide spectrum  
of biological activities, namely antioxidant, antibacterial, anti-
inflammatory, immunosuppressive and anticancer. Phloretin, a very 
bioactive chalcone has been tested against human melanoma cell 
lines, and displayed apoptotic effect against the cancer cells [114] 
(Table 7). This same compound was found to potentiate the effect 
of paclitaxel, an anticancer commercial drug that inhibits cell 
mitosis [115]. Arbutin also displayed a remarkable effect against 
melanoma cell lines by down regulating cancer genes [116]. 
Szliszka et al. [117] tested 2 chalcones (chalcone and 2’,6’dihydroxy-
4’-methoxychalcone) and 3 dihydrochalcones (2’,6’-dihydroxy-4’4-
dimethoxydihydrochalcone, 2’,6’-dihydroxy-4’-methoxydihydro- 
chalcone, and phloretin) against human prostate cancer cells and 
discovered that all the compounds induced TRAIL mediated 
apoptosis against the cell lines. Synthetic chalcones have also been 
the target of many studies. Although they are synthesized in 
laboratorial conditions and not isolated from plants, their effect on 
various cell lines has also been satisfactory [118-121]. In 2011, 
Orlikova et al. [122] published a review regarding the chemo- 
preventive and chemotherapeutic potential of dietary chalcones, 
where all the studies surrounding the effects of chalcones against 
cancer (in vitro and in vivo) were compiled. The authors concluded 
that some chalcones could intervene in a beneficial way in several 
steps of carcinogenesis and could be included in anticancer 
therapies. Moreover, the chalcones should be extensively studied in 
order to identify and characterize the naturally occurring ones while 
laboratorial synthesis to potentiate their effects should also be 
encouraged. 
4.6. Stilbenes
 This small group of compounds, although comprised of 
hundreds of compounds, one of them stands high above the others, 
resveratrol. This compound, mainly found in grapes has been 
described as a chemopreventive and chemotherapeutic agent (Table 8).
The first record of its chemopreventive activity dates back to 1997 
[123]. Since then, resveratrol and its analogues have undergone 
assays for virtually all human cancers. It has been screened in vitro
against kidney and breast cancer [124], leukemia [125] and many 
others. In murine models, resveratrol also exhibits good anticancer 
effects and is also described as a sensitizer for anticancer drugs 
[126]. Resveratrol has taken part in various epidemiological studies, 
namely for gastro intestinal tumors [127], colorectal cancer [128], 
Table 6. Xanthones with reported antitumor activity.
Compound Type of Tumor Type of Assay Result Summary Reference
-Mangostin
-Mangostin
-Mangostin
Colon carcinoma
Leukemia
Melanoma
Neck carcinoma
Glioblastoma
In vitro human cell lines ApoptosisCell cycle arrest
[103]
[104]
[105]
[106] 
[107]
[108]
[109]
Garcinone E
Hepatocellular carcinoma
Lung carcinoma
Gastric carcinoma
In vitro human cell lines ApoptosisCell cycle arrest [111]
Isomorellin
Isomorellinol
Forbesione
Gambogic acid
Cholangiocarcinoma In vitro human cell lines ApoptosisCell cycle arrest [112]
Table 7. Chalcones with reported antitumor activity.
Compound Type of Tumor Type of Assay Result Summary Reference
Melanoma In vitro human cell lines Apoptosis [114]
Phloretin
Hepatoma In vitro human cell lines Enhancement of anticancer drug [115]
Arbutin Melanoma In vitro human cell lines Down regulation of cancer genes [116]
Chalcone
2’,6’dihydroxy-4’-methoxychalcone
2’,6’-dihydroxy-4’4-dimethoxydihydrochalcone 2’,6’-
dihydroxy-4’-methoxydihydrochalcone Phloretin
Prostate carcinoma In vitro human cell lines TRAIL mediated apoptosis [117]
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as a preventive measure against cancer [129]. Due to the multitude 
of results of the various types of assays, resveratrol has been a 
target of many anticancer reviews [130-132]. Pterostilbene and 
piceatannol, which belong to the stilbene group, have also been 
described as chemopreventive and chemotherapeutic agents both  
in vitro and in vivo [133, 134]. Other stilbenes have also been 
investigated less extensively, but have also shown some type of 
anticancer effects, such as the compounds like sophrastilbene, -
viniferin, -viniferin, rhaponticin [135], 3,4,5-trimethoxy-4’bromo-
cis-stilbene [136] and 3,5-dihydroxy-4’-acetoxy-trans-stilbene 
[137], although very limited feedback was reported in murine 
xenografts. 
4.7. Lignins
 Lignins are possibly the least studied polyphenols group in 
terms of chemoprotective and chemotherapeutic potential. To the 
authors knowledge only one study was conducted to investigate the 
chemopreventive effect of Kraft lignins (Table 9). In that study, 
lignins resulting from chemical treatment of wood and paper were 
tested for adsorption to N-nitrosamines in healthy human and 
murine cell lines in order to prevent tumorigenesis arising from 
nitrosamines. Koiková et al. [138] reported that the good binding 
of the lignins revealed protective effects of the cell’s DNA.
4.8. Lignans
 Mammalian lignans are the result of metabolisation of dietary 
lignans and both display beneficial effects on human health. 
Mammalian lignans were discovered in human urine around 1980, 
and by 1998, various experiments had been conducted using lignans 
as beneficial compounds. Among these investigations, the role of 
two dietary lignans (secoisolariciresinol and matairesinol) had been 
tested both in vitro and in vivo against breast, colon and skin 
cancer, and while the in vitro assays showed good inhibition 
concentrations, the in vivo results were, at the time, still scanty 
[139] (Table 9). Since then, other dietary lignans have been  
studied for their chemopreventive and chemotherapeutic effects. 
Syringaresinol has been tested in vitro against leukemia and 
displayed cell cycle arrest at G1 phase mediated by cyclin-
dependent kinases, followed by apoptosis demonstrated by 
morphological changes in a dose and time dependent manner, 
making this polyphenol a good candidate as a chemotherapeutic 
agent [140]. Another lignan, hydroxymatairesinol, has been tested 
in murine models with induced prostate cancer. The mice fed with 
hydoxymatairesinol displayed smaller tumors as well as a halt in 
tumor growth and in some cases regression [141]. One of the most 
studied lignans is podophyllotoxin for its beneficial effect against 
cancer. It is used as a starting compound to synthetize two 
commercial anticancer drugs, etoposide and teniposide [142]. The 
in vivo application of this polyphenol has resulted in tumor 
regression in murine models, although tumor regrowth would take 
place after treatment. Other limitations such as poor solubility in 
water and tumor resistance have inspired clinicians and scientists to 
develop water soluble compounds to overcome its solubility [143], 
and to join podophyllotoxin with other molecules like fatty acids to 
overcome tumor resistance and improve pharmacological efficacy 
[144]. In terms of epidemiological studies, podophyllotoxin is used 
in anticancer preparations along with other chemicals [145-148]. 
Landete [149] reviewed the lignans, from their sources, dietary 
intake, metabolism, metabolization to mammalian lignans, health 
implications and future prospects. The author covered the effects on 
colon, breast, prostate and intestinal cancer, which seem to be the 
most effective targets of this polyphenol. In terms of future 
perspectives, the author advised investigation to uncover the 
mechanisms of action at a molecular level as well as a closer look 
into nutrigenomics and nutrigenetics. 
4.9. Flavonoids
4.9.1. Flavonols
 The most active flavonols against cancer are quercetin and 
kaempferol (Table 10). They have been extensively studied against 
Table 8. Stilbenes with reported antitumor activity.
Compound Type of Tumor Type of Assay Result Summary Reference
Leukemia
Mammary carcinoma
Skin carcinoma
In vitro human cell lines
In vivo murine xenografts
Cell differentiation induction
Inhibition of preneoplastic lesions
Tumorigenesis inhibition
[123]
Resveratrol
Breast carcinoma
Kidney carcinoma
In vitro human cell lines
In vivo murine xenografts Promotion of Argonaute2 expression [124]
Leukemia In vitro human cell lines
Apoptosis
Cell cycle arrest [125]
Neuroblastoma
Glioma
Pancreatic carcinoma
Breast carcinoma
Prostate carcinoma
Leukemia
Renal carcinoma
In vitro human cell lines Sensitizer of anticancer drugs [126]
Gastrointestinal carcinomas Epidemiological studies Ongoing [127]
Colorectal carcinoma Epidemiological studies Undisclosed results [128]
Resveratrol
Healthy individuals Epidemiological studies
Lower doses of resveratrol (1.0, 2.5 and 5.0 g) 
are detectable in human plasma [129]
Sophrastilbene
-viniferin
-viniferin
Rhaponticin
Squamous cell carcinoma
Submandibular glad carcinoma
Leukemia
In vitro human cell lines Toxicity against cancer cells
Activation of caspases [135]
3,4,5-trimethoxy-4V-bromo-
cis-stilbene Lung carcinoma In vitro human cell lines
DNA fragmentation
Apoptosis [136]
3,5-dihydroxy-4’-acetoxy-
trans-stilbene
Prostate carcinoma
Melanoma
In vitro human cell lines
In vivo murine xenografts Limited potential in vivo [137] 
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various murine and human cell lines with remarkable effects. Back 
in 1994, quercetin proved to be effective against chronic myeloid 
leukemia, Molt-4 acute lymphocytic leukemia, Raji Burkitt 
lymphoma in terms of morphological changes, condensation of 
nuclear chromatin, nuclear fragmentation and induced apoptosis in 
a time and concentration dependent manner [150]. Since then, 
quercetin has been investigated in various human cell lines. Tan et
al. [151] reported an inhibition of tyrosine kinase and of important 
steps in angiogenesis like proliferation, migration, and tube 
formation of human microvascular dermal endothelial cells in 
human gastric adenocarcinoma, hepatocellular carcinoma and lung 
adenocarcinoma. Severe and moderately aggressive human prostate  
cancer cell lines were also inhibited by quercetin through inhibition 
of specific oncogenes and genes that control the cell cycle [152]. 
Quercetin is known to be metabolized during the human digestion 
and also has a very poor solubility. These drawbacks have led 
research groups to attempt to derive this compound, create 
complexes with metals or to encapsulate it in lipossomes. 
Derivatives like quercetin-5’,8-disulfonate, proved to have 
anticancer properties in colon and breast cancer cell lines, by 
arresting the cell cycle, surpassing quercetin itself [153]. Tan et al.
[154, 155] have combined quercetin with both copper and zinc and 
reported that these complexes were cytotoxic for the cancer cell 
lines and by binding to the DNA induced apoptosis and growth 
inhibition. Finally, Yuan et al. [156] proposed encapsulation of 
quercetin in polyethylene glycol 4000 lipossomes to overcome its 
poor solubility. The methodology involved intravenous (i.v.) 
injecting with subsequent accumulation in the tumor cells. In vivo
assays with mice suffering from Lewis lung cancer, colon 
adenocarcinoma and hepatoma were performed. Apoptosis and 
Table 9. Lignins and lignans with reported antitumor activity.
Compound Type of Tumor Type of Assay Result Summary Reference
Kraft lignins
Sane human skin cells
Quasidiploid hamster cells
In vitro human cell lines
In vitro murine cell lines
Adsorption to nitrosamines
DNA protective effect
[138]
(-)Syringaresinol Leukemia In vitro human cell lines
Cell cycle arrest
Apoptosis
[140]
7-Hydroxymatairesinol Prostate carcinoma In vivo murine models
Cell proliferation reduction
Tumor reduction
[141]
Podophyllotoxin and polyethylene 
glycol 
Leukemia
Lung carcinoma
In vitro human cell lines
In vivo murine models
Better tumor inhibition compared to 
podophyllotoxin alone [143]
Podophyllotoxin and fatty acids 
analogs
Solid tumors
Leukemia
In vitro human cell lines
Cytotoxicity towards cancer cells
Low cytotoxicity towards sane cells
[144]
Table 10. Flavonols with reported antitumor activity.
Compound Type of Tumor Type of Assay Result Summary Reference
Leukemia
Raji Burkitt lymphoma In vitro human cell lines
Morphological changes Condensation of nuclear chromatin
Nuclear fragmentation
Apoptosis
[150]
Gastric adenocarcinoma 
Hepatocellular carcinoma
Lung adenocarcinoma
In vitro human cell lines
Inhibition of tyrosine kinase and of important steps of 
angiogenesis like proliferation, migration, and tube formation 
of human microvascular dermal endothelial cells in human
[151]
Various cancers Epidemiological studies Decrease in -fetoprotein [157]
Quercetin
Prostate cancer In vitro human cell lines Inhibition of oncogenes and genes controlling the cell cycle [152]
Quercetin and quercetin-5’,8-
disulfonate
Colon cancer
Breast cancer In vitro human cell lines Cell cycle arrest [153]
QC12 (3’-(N-
carboxymethyl)carbamoyl-3-
4’-5-7-tetrahydroxyflavone)
Various cancers Epidemiological studies Quercetin bioavailability between 20 and 25% in plasma [158]
Quercetin copper(II) complex Lung adenocarcinoma In vitro human cell lines
Cytotoxic for the cancer cell lines
DNA binding
Apoptosis and growth inhibition
[155]
Quercetin in polyethylene 
glycol 4000 lipossomes
Lewis lung cancer
Colon adenocarcinoma Hepatoma In vivo murine models
Apoptosis
Growth inhibition [156]
Hepatocarcinoma In vitro human cell lines Cell viability reduction [159]
Kaempferol
Pancreatic carcinoma In vitro human cell lines
Growth enzymes inhibition
Apoptosis [160]
Kaempferol+TRAIL
Colon cancer
Prostate cancer In vitro human cell lines Caspase dependent apoptosis [161]
Kaempferol Osteosarcoma
In vitro human cell lines
In vivo murine models
Cell viability reduction
Ca2+ increase
Alteration of protein expression
Apoptosis
[162]
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growth inhibition was detected for all tumors, thus eliminating a 
considerable drawback in the application of quercetin for cancer 
treatment. In terms of epidemiological studies involving quercetin, 
the first one was conducted in 1996, this Phase I clinical trial 
involved 51 patients with various terminal cancers. They were 
administered i.v. escalating doses of quercetin with a maximum of 
1700 mg/m2 for three weeks. Nephrotoxicity was detected at the 
maximum concentration and a recommended concentration was 
fixed at 1400 mg/m2 for future type II trials. In one patient CA-125 
(biomarker for ovarian cancer) was significantly reduced, and all 
the patients suffering from hepatocellular carcinoma revealed a 
reduction of -fetoprotein, which is usually high in these types of 
cancer. Although this was an interesting finding, no regression in 
the tumor was detected in radiological assays [157]. In 2001, 
Mulholland et al. [158], confronted with the usage of DMSO 
(Dimethyl sulfoxide), which is known to cause hemolysis, to 
overcome the staggering low solubility of quercetin in water, 
synthesized a quercetin derivative, QC12 (3’-(N-carboxymethyl) 
carbamoyl-3-4’-5-7-tetrahydroxyflavone). The authors administered 
400mg of this compound to six terminal state cancer patients 
through either oral or i.v.. At this concentration, the authors found 
no evidence of toxicity towards the patients and, although i.v. 
administered QC12 had a bioavailability 20~25% of quercetin, the 
orally administered one was not found in the plasma. They 
postulated that other derivatives should be researched in order to 
potentiate bioavailability of quercetin. 
 Kaempferol has also been studied for potential anticancer 
properties. In terms of human cell lines, kaempferol proved to be 
effective against hepatocarcinoma. This type of tumor is known to 
create hypoxia to surrounding cells, therefore promoting its own 
growth and making it resistant to chemotherapy. Kaempferol 
proved to reduce tumor cell viability even under hypoxic conditions 
[159]. In two types of human pancreatic cell lines, kaempferol 
proved to be better than 5-FU (fluorouracil, an anticancer drug) by 
inhibiting growth enzymes and promoting apoptosis in a 
concentration dependent manner [160]. Kaempferol can also be 
joined with anticancer agents, like TRAIL; in a study published in 
2008, Yoshida et al. [161] reported that the combined effect of 
these two compounds induced considerable caspase dependent 
apoptosis rates in colon and prostate cancer cell lines, whilst the 
individual compounds were very poor in apoptosis induction. As a 
control assay they tested kaempferol+TRAIL in normal peripheral 
blood mononuclear cells with low toxicity to these sane cells. 
Human osteosarcoma cell lines have also been inhibited by 
kaempferol, namely by loss of cell viability, increase in cytoplasmic 
Ca2+, alteration of certain protein expression and apoptosis. In vivo
studies have also been trialed and a reduction in osteosarcoma 
tumor growth was detected [162].
4.9.2. Flavones
 The major representative molecule within the flavones is 
chrysin. It has demonstrated good results in various types of cancers 
(Table 11). It induced caspase 3 mediated apoptosis and enhanced 
Akt phosphorylation by inhibiting Pi3k (enzyme responsible for 
cell growth) in human leukemic cell lines [163]. Like kaempferol, 
chrysin can also be joined with TRAIL to enhance anticancer 
effects. In 2011, Li et al. [164] used human nasopharyngeal 
carcinoma, colorectal cancer, cervix carcinoma and hepatoma cell 
lines to test the synergy of these compounds. Although there was no 
observed effect for the isolated compounds, the treatment with the 
mixture of both enhanced apoptosis in four cell lines. In an attempt 
to understand the mechanisms behind this synergy, the authors pre-
treated the cells with chrysin before adding TRAIL which resulted 
in weak results, implying that cell death was enhanced by chrysin 
but induced by TRAIL. 
 In terms of murine models, chrysin has yielded good results 
against diethylnitrosamine (DEN) induced heptocarcinogenesis; 
250 mg/kg (body weight) of chrysin was administered to the mice 
and changes in enzymes and protein expression were detected, as 
well as a reduction in number and size of nodules formed, pointing 
Table 11. Flavones with reported antitumor activity.
Compound Type of Tumor Type of Assay Result Summary Reference
Chrysin Leukemia In vitro human cell lines Caspase 3 mediated apoptosis [163]
Chrysin + TRAIL
Nasopharyngeal carcinoma 
Colorectal cancer, Cervix 
carcinoma Hepatoma
In vitro human cell lines Enhancement of apoptosis [164]
Hepatocarcinogenesis In vivo murine models
Changes in enzymes and protein expression Reduction
in number and size of nodules [165]
Chrysin
Hepatocellular carcinoma In vivo murine models
Attenuated biochemical and histological changes
Reduction of -fetoproteins and embriogenic antigen [166]
Flavopiridol 60 different cell lines
In vitro human cell lines
In vitro murine cell lines
In vivo murine models
Cytotoxicity against tumor cell lines
Tumor inhibition [167]
Flavone core structure Colon adenocarcinoma In vitro human cell lines
Reduction of cell proliferation
Induction of apoptosis [168]
Pectolinarin, Linariin, Isolinariin 
A, Isolinariin B, 
Paracetylpectolinarin, 
Pectolinarigenin, Pectolinarigenin-
7-O--Glucoside, Antirrhide and 
Antirrhinoside
Large lung cell carcinoma 
Hepatocellular carcinoma
Renal adenocarcinoma 
Amelanotic carcinoma
Colorectal adenocarcinoma
In vitro human cell lines Reduction of cell proliferation [169]
Chrysing long chain derivatives Liver carcinoma In vitro human cell lines Antiproliferative activity [170]
Leukemia In vivo murine models Tumor supression [171]
Flavone acetic acid
Various human carcinomas Epidemiological studies No reported benefitial effects [174]
P276-00 Various human carcinomas
In vitro human cell lines
In vivo murine models Antiproliferative potential [177]
P276-00 Breast carcinoma Epidemiological studies Ongoing [178]
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out a hepatoprotective and chemopreventive activity of this 
flavonol [165]. The same effect was reported in another study 
involving chrysin and murine models, where hepatocellular 
carcinoma was induced by N-nitrosodiethylamine in mice which 
were then treated with chrysin, resulting in attenuated biochemical 
and histological changes when compared to the control group. 
Moreover, chrysin reduced the levels of -fetoproteins and 
embriogenic antigen (tumor markers). Finally, the most remarkable 
effect was a restoration of cell architecture of liver tissue, 
confirming a chemotherapeutic effect [166].  
 Flavopiridol, another effective flavonol has also been used both 
in vitro and in vivo against various cancers. Drees et al. [167] tested 
this compound in vitro against 60 different cancer cell lines. For a 
control assay they used sane bone marrow cell lines which only 
displayed sings of toxicity for concentrations above 100 ng/ml. 
Flavopiridol displayed cytotoxicity at concentrations as low as 0.1 
ng/ml, especially in prostate and melanoma xenografts. Moreover, 
14 of the 23 tumor cell types were inhibited in a greater manner 
than the control bone marrow cells. The in vivo assays were only 
performed in prostate cancer, which was the most affected under in 
vitro assays. In this case, flavopiridol was administered in the 
maximum tolerated dose (19 mg/kg) to have significant activity and 
after the administration the tumor regrew, implying that treatment 
should be longer than 2 weeks. 
 The core structure of flavones (2-phenyl-4H-benzopyran-4-
one), a flavone, also indicated some antitumor activity against 
human colon adenocarcinoma by reducing cell proliferation and 
induction of apoptosis in a greater manner than campothecin 
(alkaloid based anticancer drug) [168]. 
 In 2005, Tundis et al. [169] isolated all the flavones and 
respective derivatives from the plant Linaria reflexa, including 
pectolinarin, linariin, isolinariin A, isolinariin B, paracetylpectolinarin, 
pectolinarigenin, pectolinarigenin-7-O--glucoside, antirrhide and 
antirrhinoside, screening them against large lung cell carcinoma, 
hepatocellular carcinoma, renal adenocarcinoma, amelanotic 
carcinoma, colorectal adenocarcinoma and sane human fetal lung 
tissue as a control. All the compounds displayed interesting results 
against colorectal carcinoma and large lung cell carcinoma; 
pectolinarin was also effective against amelanotic melanoma. 
Pectolinarigenin and its derivatives were active against amelanotic 
melanoma and large lung cell carcinoma. The less sensitive cell line 
was renal adenocarcinoma. 
 In order to overcome the limitations of natural compounds in 
terms of bioavailability and cytotoxic effects, many research groups 
have started synthesizing compounds based on natural ones but 
removing structural limitations. Lv et al. [170] synthesized long 
chain derivatives of chrysin and tested them against human  
liver cancer. Among them, the compounds that had a higher  
activity were hexadecyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-
7-yloxy)acetate and N-hexadecyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-
chromen-7-yloxy)acetamide displaying antiproliferative activity 
comparable to arlotinib (anticancer drug). Furthermore, they used 
docking simulations to determine the binding mode of these 
compounds and determined that both these compounds bonded 
quite well with the epidermal growth factor receptor (EGFR) 
postulating that they could be interesting chemotherapeutic agents.
 To this date, not many flavones have been subject to 
epidemiological studies, except flavone acetic acid. In the mid 80’s, 
dozens of flavones from Lyonnaise Industrielle Pharmaceutique 
were subjected to preliminary screening against murine leukemia. 
Among all the compounds tested, flavone acetic acid had the 
greatest activity and continued to a phase I murine study that 
through pharmacokinetics confirmed that a quick hydrolysis of this 
compound was responsible for tumor suppression. In addition, no 
myelosupression or major toxicity was detected. When the clinical 
trials escalated to human subjects, there was no antitumor activity, 
but this limitation was not due to poor penetration. Further studies 
confirmed that the mechanisms of action in murine and human 
species were different, leading to its poor activity in humans, and 
inspiring research groups to pursue the underlying mechanisms of 
this promising drug in the human body [171-176].  
 Recently, a flavone derivative has been tested against various 
cell lines and xenografts; this compound, P276-00 has yielded 
excellent results, with an antiproliferative potential of 30-fold 
higher than cisplatin (a chemotherapeutic drug) and 26-fold higher 
tumor sensitivity. This compound has been tested against cisplatin 
resistant tumors of central nervous system, melanoma, prostate and 
renal cancers, among others. Due to the outstanding results of this 
molecule, in 2011, a clinical trial was started to determine the 
effects of P276-00 administered in escalating doses with two 
anticancer drugs (Gemcitabine and Carboplatin) in subjects with 
metastic breast cancer [177, 178]. 
4.9.3. Flavanols
 Most of the compounds in this group derive from the catechin 
backbone being the most abundant compounds found in green tea. 
Despite the widely accepted benefits of these compounds for cancer 
treatment, reports of the beneficial effects of isolated compounds 
are not that abundant. With regard to catechin, it is known to 
prevent metastasis of melanoma in murine models (Table 12). This 
compound inhibits tumor formation and increases the life span of 
the animals. In vitro tests uncovered that catechin also inhibits the 
migration of melanoma cells across the collagen matrix of a 
Boyden chamber [179]. A catechin derivative, catechin hydrate, 
was effective in inhibiting by 50%, the growth of human cervical 
cancer cell lines in vitro, by increasing caspase-3, -8 and -9 and by 
inducing apoptosis [180]. Despite the scarce studies on the isolated 
effects of catechin, there is a considerable amount of publications 
regarding conjugations of this compound with a variety of other 
molecules. In 2004, Farivar-Mohseni et al. [181] used the known 
ability of catechin to inhibit cyclooxygenase (prostanoid producing 
enzyme) and conjugated it with NS-398 (also a prostanoid 
inhibiting enzyme) and tested their synergistic capacity against 
various bladder and prostate cancer cell lines. For both cancer 
types, the synergy was evident, resulting in a reduction in cell 
growth and apoptosis in a more severe manner than with the 
isolated compounds. Catechin has also been joined with inositol 
hexaphosphate (a carbohydrate) against pancreatic cancer cell lines. 
This conjugate increased apoptosis and inhibited cell growth in a 
greater manner that the isolated compounds [182]. Vittorio et al.
[183] used dextran, a branched glucan in conjunction with catechin 
against pancreatic ductal adenocarcinoma. The cancer line was 
killed after being exposed to this conjugate. Moreover, dextran-
catechin was less toxic to normal pancreatic cells than catechin 
alone. Anticancer clinical trials using catechin as an anticancer or 
cancer preventive drug are extensive, although in some cases, there 
is no way of knowing if the drug is strictly composed by catechin or 
if derivatives like epigallocatechin, epigallocatechin-3-gallate and 
other are also present. A great number of these trials intend to 
assess the preventive effects of catechin against unspecific cancers 
[184], and on specific types of cancer, like cervical and esophageal 
[185,186]. Finalized studies using catechin as an experimental drug 
have studied bladder and prostate cancer [187-189]. An ongoing 
study, with a primary due date scheduled for January 2013 is 
studying the effect of catechin in colorectal cancer [190].
 Epigallocatechin-3-gallate (EGCG) is known for being the most 
abundant flavanol in tea and for a wide range of health benefits. It 
has been tested against human eosinophilic leukemia cell lines and 
suppressed cell proliferation in a dose dependent manner. At a low 
concentration of 40 M the tumor cells underwent differentiation 
into mature eosinophil-like cells [191]. This compound also 
exhibited a considerable apoptotic effect against mouse hepatoma 
cell lines by cleaving procaspase-12 and increase in phosphorylation 
of ElF2 (subunit of ElF2 protein, responsible for an important 
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regulator of translation initiation) [192]. Ellis et al. [193] uncovered 
the underlying EGCG-induced melanoma inhibition mechanism by 
using EGCG against melanoma cancer cell lines. According to 
these authors, the downregulation of inflamasommes (multiprotein 
oligomer) decreases the secretion of IL-1 (a cytokine) which in 
turn decreases the activity of NF-kB that finally reduces cell 
growth. (-) Epigallocatechin-3-gallate monoesters (EGCG-C4, 
EGCG-C8 and EGCG-C16) were synthesized by Matsumura et al.
[194] in order to overcome the poor stability of EGCG. In vitro
studies pointed out a better stability for EGCG-C16 by inhibiting 
cell proliferation, inducing apoptosis and less production of 
hydrogen peroxide against colorectal carcinoma. Likewise, in 
murine models this compound was the most potent in tumor 
reduction. The undeniable contribution of EGCG has been gathered 
and reviewed by Singh et al. [195] describing that EGCG could 
fight cancer through various mechanisms, namely an antioxidant 
potential, induction of apoptosis and cell cycle arrest, effect against 
phase I and II enzymes, modulation of intracellular signaling 
cascades, inhibition of epigenetic modifications, inhibition of 
dihydrofolate reductase and telomerase, inhibition of angiogenesis, 
modification of miRNA expression and other miscellaneous 
mechanisms. The chemopreventive and anticancer effects of 
epigallocatechin-3-gallate have also been assessed through clinical 
trials, against metachronous adenomas of the colorectum, breast 
and small cell lung cancer [196-198]. 
4.9.4. Isoflavones
 Genistein and daizedin are the major compounds of the 
isoflavones and have been described as having antitumor activity 
and sensitizing effects (Table 13). Genistein, the most common 
compound in soy has been tested against prostate cancer cell lines, 
and resulted in inhibition of cell proliferation in a dose dependent 
manner as well as upregulation of glutathione peroxidase and 
downregulation of apoptosis inhibitors and DNA topoisomerase 
[199]. Murine models have also been used to assess the effects of 
genistein. Wang et al. [200] attempted to describe the effects to 
lifetime exposure of different doses of genistein (0, 25 and 250 
mm/kg body weight) in rats. These concentrations were given to 
rats for 11 months, after which they were injected with N-
methylnitrosourea to induce prostate cancer. The rats which had 
consumed the higher dosage of genistein had less prostate and other 
tumor incidence when compared to the control ones. Another 
remarkable effect of genistein is the capacity to sensitize tumors for 
other anticancer medication like gemcitabine and cisplatin, namely 
against pancreatic, ovarian and cervical cancers. In addition, it also 
potentiated the effects of TRAIL [201-205]. In 2008, Banerjee et al.
[206], reviewed the in vitro targets of genistein in apoptosis, cell 
cycle arrest and transcription factors as well as the effects of 
angiogenesis, metastasis and sensitizing effects, based on previous 
studies. Two more reviews were published regarding the effect of 
genistein on cancer, revising the in vitro, in vivo and clinical trials 
in which this compound has been involved. Both indicate that 
despite the remarkable effect of this compound on in vitro and in 
vivo assays, clinical trials have failed to come up with standardized 
methods to test this compound, making it difficult to draw 
satisfactory conclusions and urging researchers to rethink and 
design common clinical trials for this natural compound [207, 208]. 
The clinical trials against cancer using genistein studied both the 
joint activity of genistein with other drugs (gemcitabine and 
Table 12. Flavanols with reported antitumor activity.
Compound Type of Tumor Type of Assay Result Summary Reference
Catechin Melanoma
In vitro human cell lines
In vivo murine models Metastasis prevention [179]
Catechin hydrate Cervical carcinoma In vitro human cell lines Inhibition of 50% of cell growth [180]
Catechin+NS-398
Bladder carcinoma
Prostate carcinoma In vitro human cell lines
Cell growth reduction
Apoptosis [181]
Catechin+Inositol 
hexaphosphate Pancreatic carcinoma In vitro human cell lines
Cell growth reduction
Apoptosis [182]
Catechin+dextran Pancreatic ductal adenocarcinoma In vitro human cell lines Apoptosis [183]
Unspecific solid tumors Epidemiological studies Green tea may have ingredients that may prevent cancer [184]
Cervical carcinoma Epidemiological studies Undisclosed results [185]
Esophageal carcinoma Epidemiological studies Ongoing [186]
Bladder carcinoma Epidemiological studies
Green tea may have ingredients that slow the growth of 
certain cancers [187]
Epidemiological studies Undisclosed results [188]
Prostate carcinoma
Epidemiological studies
Green tea contains ingredients that may prevent or slow 
the growth of this cancer [189]
Catechin
Colorectal carcinoma Epidemiological studies Ongoing [190]
Epigallocatechin-3-
gallate Leukemia In vitro human cell lines
Proliferation suppression
Cell diferentiation [191]
Hepatoma In vitro murine cell lines
Apoptosis
Phosphorylation of ElF2 [192]Epigallocatechin-3-
gallate
Melanoma In vitro human cell lines
Downregulation of inflamasommes
Mechanism of action [193]
(-) Epigallocatechin-3-
gallate monoesters Colorectal carcinoma In vitro human cell lines
Inhibition of cell proliferation Apoptosis induction 
Reduction in hydrogen peroxide production [194]
Metachronous adenomas of the colorectum Epidemiological studies Ongoing [196]
Breast carcinoma Epidemiological studies Ongoing [197]
Epigallocatechin-3-
gallate
Lung carcinoma Epidemiological studies Ongoing [198]
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erlotinib) and the pharmacokinetics of this drug, along with the 
traditional trials against bladder, breast and pancreatic cancer [209-
213]. Currently, on-going clinical trials are studying genistein 
against prostate, bladder, lung and kidney cancers, as well as 
melanoma [214-218]. 
 Daidzein has also been studied against cancer, but to a shorter 
extent when compared to genistein. It has shown in vitro activity 
against breast cancer by inhibiting proliferation in G1 and G2 
phases and increase in caspase-9 activity [219]. Similar activity was 
detected both for prostate and colon cancer, this last one being one 
of the most common cancers in the world, with poor response too 
chemotherapeutic agents [220, 221]. Mammary human xenografts 
have also been sensitive do daidzein,with tumor inhibition and 
apoptosis described [222]. The preventive capacity of this 
compound was assessed by Constatinou et al. [223] by joining it 
with tamoxifen and administrating it to mice with induced 
mammary tumors. The authors concluded that this mixture reduced 
tumor multiplicity by 76%, incidence by 35%, tumor burden and 
latency by 95% and 62%, respectively. These favorable results 
haven’t been translated into extensive clinical trials. 
4.9.5. Flavanones
 The anticancer potential of flavanones hasn’t been studied  
to the same extent as the other flavonoids, although some activity 
has been reported, especially on hesperidin and 2’-OH flavanone 
(Table 14). Itiogawa et al. [224] carried out a screening of  
10 flavanones (Sophoraflavanone-B, Senegalensein, Amorilin, 
Euchrestaflavanone-A, Lupinifolin, Lupinifolinol, Paratocarpin-I, 
Erythrisenegalone, Citflavanone and Yukovanol) against human 
Raji cells infected with Epstein-Barr virus (EBV). This virus is 
associated with a high risk of various cancers. All the flavanones 
exhibited inhibitory effect against the infected cells without 
showing toxicity towards the normal cells. Furthermore, in murine 
models, only lupinfolin showed tumor inhibition against the 
induced tumors. Another screening involving Raji cells infected 
with EBV and flavanones (Munduleaflavanone A, Prostratol F and 
40-O-Geranylnaringenin among others) resulted in inhibition of 
infected cells proliferation in a dose dependent manner [225]. 
Hesperidin, one of the most studied flavanones has been described 
as an in vitro inhibitor of human nasopharyongeal carcinoma 
epithelial cells and mammary carcinoma cell lines by arresting cell 
growth, inducing apoptosis and expressing caspase-3 [226, 227]. 
Shen et al. [228], carried out in vitro and in vivo studies with 8 
flavanones (2’-OH flavanone; 4’-OH flavanone; 6-OH flavanone; 
7-OH flavanone; Naringenin; Nargin and Toxifolin) against various 
cell lines of human colon adenocarcinoma. The in vitro study 
pointed out excellent inhibition constants for 2’OH flavanone and 
apoptosis via caspase-3 and very little toxicity towards sane cells. 
Murine models were used to induce colon adenocarcinoma, and 
after tumor growth, flavanones were administered. 2’-OH 
Flavanone was once again the compound with the highest inhibition 
rates by triggering apoptosis and increasing p21. A very similar 
study was carried out by Hsiao et al. [229] in 2007, where various 
flavanones were screened against human lung adenocarcinoma, 
Lewis lung adenocarcinoma, murine lung adenocarcinoma, human 
gastric epithelial adenocarcinoma and human hepatocellular 
Table 13. Isoflavones with reported antitumor activity.
Compound Type of Tumor Type of Assay Result Summary Reference
In vitro human cell lines Proliferation inhibitionDownregulation of apoptosis inhibitor [199]Genistein Prostate carcinoma
In vivo murine models Less incidence of prostate cancer and other carcinomas [200]
Growth inhibition
Apoptosis [206]Genistein + Gemcitabine Pancreatic carcinoma In vitro human cell linesIn vivo murine models
Downregulation of NF-kB [202]
Ovarian carcinoma In vitro human cell lines Inhibition of survivin [203]
Genistein + Cisplatin
Cervical carcinoma In vitro human cell lines Inhibition of NF-kBInhibition of Akt/mTOR pathways [204]
Genistein + TRAIL Glioma In vitro human cell lines Facilitation of TRAIL-mediated apoptosis [205] 
Genistein + Gemcitabine Breast carcinoma Epidemiological studies Undisclosed results [209]
Bladder carcinoma Epidemiological studies Undisclosed results [210]
Genistein
Breast carcinoma Epidemiological studies Undisclosed results [211]
Genistein + Gemcitabine
Genistein + erlotinib Pancreatic carcinoma Epidemiological studies Undisclosed results [213]
Genistein Epidemiological studies Undisclosed results [214]
Genistein + Quercetin
Prostate carcinoma
Epidemiological studies Ongoing [215]
Genistein Bladder carcinoma Epidemiological studies Ongoing [216]
Genistein + Gemcitabine Lung carcinoma Epidemiological studies Ongoing [217]
Genistein + Interleukin-2 MelanomaKidney carcinoma Epidemiological studies Ongoing [218]
Breast carcinoma In vitro human cell lines Cell proliferation inhibitionG1 and G2 phases arrest [219]Daidzein
Prostate carcinoma In vitro human cell lines Angiogenesis inhibition [220]
Colon carcinoma In vitro human cell lines Caspase-3 activity increaseCell growth inhibition [221]
Breast carcinoma In vivo murine models Tumor inhibitionApoptosis [222]
Daidzein
Mammary carcinoma In vivo murine models Reduction in tumor multiplicity, incidence, burden and latency [223]
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adenocarcinoma. Once again the 2’-OH flavanone was the best 
inhibitor of all the cancer cell lines by arresting the cell cycle and 
promoting the reduction of cyclin B, D and Cdc2 (proteins that 
control progression of cells through the cell cycle). The authors 
then tested this compound in nude mice with Lewis lung tumors. 
After 8 and 17 days, the mice treated with the flavanone displayed 
smaller tumors than the control group. 
 The authors are unaware of any finished or ongoing anticancer 
clinical trials using flavanones as drugs, this may be due to the little 
reports of in vitro and murine assays regarding this group of 
flavonoids. Although, as stated above there are some interesting 
results regarding hesperidin and 2’-OH flavanone; more studies 
regarding these compounds should be carried out.
4.9.6. Anthocyanidins
 Various compounds of this family have also been thoroughly 
studied for anticancer properties (Table 15). Many of them have 
exerted chemotherapeutic properties both in vitro and in vivo.
Table 14. Flavanones with reported antitumor activity.
Compound Type of Tumor Type of Assay Result Summary Reference
Sophoraflavanone-B Senegalensein
Amorilin Euchrestaflavanone-A Lupinifolin
Lupinifolinol Paratocarpin-I Erythrisenegalone Citflavanone
Yukovanol
Human Raji cell line In vitro human cell linesIn vivo murine models EBV inhibitory effect [224]
Munduleaflavanone A
Prostratol F
40-O-Geranylnaringenin
Human Raji cell line In vitro human cell lines EBV inhibitory effect [225]
Nasopharyngeal carcinoma In vitro human cell lines Cell division inhibitionApoptosis [226]
Hesperidin
Mammary carcinoma In vitro human cell lines
Acumulation of p53
Expression of caspase-3
Cell proliferation inhibition
[227]
2’-OH flavanone
4’-OH flavanone
6-OH flavanone
7-OH flavanone Naringenin
Nargin
Toxifolin
Colon carcinoma In vitro human cell linesIn vivo murine models
Caspase-3 induction
Apoptosis
Tumor growth inhibition
[228]
2’-OH flavanone
4’-OH flavanone
6-OH flavanone
Naringin
Naringenin
Lung carcinoma
Murine lung carcinoma
Gastric carcinoma
Hepatocellular carcinoma
In vitro human cell lines
In vivo murine models
Cell cycle arrest
Reduction of cyclin B, D and 
Cdc2
Tumor reduction
[229]
Peonidine-3-glucoside Lung carcinoma In vitro human cell lines
Mobility and invasion 
reduction
Metalloproteinases reduction
[236]
Cyanidin-3-glucoside Murine skin carcinomaHuman lung carcinoma
In vitro human cell lines
In vivo murine models
Inhibition of cell proliferation
Tumor size reduction
Metastasis inhibition
[237]
Table 15. Anthocyanidins with reported antitumor activity.
Compound Type of Tumor Type of Assay Result Summary Reference
Delphinidin Prostate carcinoma In vitro human cell linesIn vivo murine models
Cell growth inhibition
Caspase mediated apoptosis
Tumor size reduction
[230]
Delphinidin-3-sabubioside Leukemia In vitro human cell lines Caspase -3, -8 and 9 activationApoptosis [231]
Cyanidin-3-rutinoside
Cyanidin-3-glucoside Lung carcinoma In vitro human cell lines Dose dependent inhibitory effect [232]
Glibenclamide Gastric carcinoma In vitro human cell lines Cell viability reductionApoptosis [233]
Cyanidin-3-O-glucoside Gastric carcinoma In vitro human cell lines Reduction of cell proliferationMorphological changes [234]
Delphinidin
Cyanidin Colorectal carcinoma In vitro human cell lines
Generation of ROS
Inhibition of glutathione reductase [235]
Peonidine-3-glucoside Lung carcinoma In vitro human cell lines Mobility and invasion reductionMetalloproteinases reduction [236]
Cyanidin-3-glucoside Murine skin carcinomaHuman lung carcinoma
In vitro human cell lines
In vivo murine models
Inhibition of cell proliferation
Tumor size reduction
Metastasis inhibition
[237]
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 Delphinidin demonstrated a caspase mediated inhibition of cell 
proliferation and apoptosis against prostate cancer cell lines [230] 
while its derivative, delphidin-3-sambubioside demonstrated a ROS 
(Reactive Oxygen Species) mediated apoptotic effect against 
leukemia cell lines as well as activation of caspase -3, -8 and -9. 
[231]. Lyanin-3-rutinoside and cyaniding-3-glucoside exhibited a 
migration and invasion inhibition on lung carcinoma cell lines 
[232]. Glibenclamide was able to reduce cell viability while 
inducing apoptosis by ROS dependent JNK enzymes against in 
vitro human carcinoma [233]. Sun et al. [234] isolated cyaniding-3-
O-glucoside from Myrica rubra and tested it against 3 types of 
gastric carcinoma cell lines, resulting in reduction of cell 
proliferation, typical apoptosis morphological changes in dose 
dependent manners. Two studies published in 2010 proved the 
anticancer effect of delphinidin, cyaniding and peonidin-3-
glucoside against colorectal and lung carcinoma with satisfactory 
results [235, 236]. Ding et al. [237] in the first anticancer in vivo
experiment with anthocyanidins used cyanidine-3-glucoside against 
human lung adenocarcinoma, displaying satisfactory results for the 
preliminary assays, with inhibition of cell proliferation and 
complete blockage of cell growth for 40 M. The authors, inspired 
by the good results, later induced skin tumors in mice, using 12-O’-
tetradecanolyphorbol-13-acetate and subsequently treated them 
with cyaniding-3-glucoside which proved to reduce tumor size and 
inhibition of metastasis. Hafeez et al. [230] also conducted assays 
on murine models implanted with prostate cancer cells, which  
later developed into tumors. Delphinidin decreased the tumor size 
and reduced the expression of NF-kB/65 nuclear translocation and 
NF-kB DNA binding activity. Despite few results regarding 
anthocyanidins as chemotherapeutic compounds, the effectiveness 
is quite remarkable and further in vivo studies should be carried  
out. To this date, the authors are unaware of any clinical trials 
regarding anthocyanidins, possibly due to few results from in vivo 
experiments. 
5. CONCLUSION
 Mankind has come a long way in the fight against cancer. The 
improvement of many therapies allied to the development of new 
drugs and treatments have assured in some cases the treatment or 
cure for certain cancers and a longer life span of patients. Yet, the 
long battle is far from over, especially due to incorrect food habits 
from the populations, along with an increase in smoking and 
pollution. Cancer cases are expected to increase in the near future, 
posing a threat for people across the globe as well as for 
governments who will have to waste astronomical funds for 
treatments if effective ones are not uncovered.
 In some cancer cases, synthetic drugs or surgery can eradicate 
the threat, but highly metastasizing and drug resistant strains keep 
escaping treatments. The toxicity of synthetic compounds is also 
difficult to overcome, eliminating promising drugs from eventual 
administration. Natural compounds, isolated from plants or 
synthesized in a laboratory can be administered to patients, usually 
without the side effects and toxicity of synthetic preparations. 
These compounds can even be added to chemical preparations to 
increase their effect or to display a sensitizing action. Some natural 
compounds have been administered with success and are case 
studies for further applications. One of the main problems with 
natural compounds is the high cost and delay of compound 
separation and isolation even before the biological activity being 
assessed [238], resulting in the waste of considerable amounts of 
money in compounds that will not have any activity. When the 
compound is finally isolated the first step to determine its 
anticancer properties is a screen against cell lines. This type of 
assay is not free of disadvantages; in fact, some authors report that 
cell cultures maintained in the same conditions may be altered over 
time, resulting in “thousands of misleading studies and potentially 
erroneous papers published” [239]. This phenomenon is transversal 
to all types of cell cultures, including the cancer cell lines. 
 The main preliminary study before anticancer compounds are 
trialed in humans, are murine models. Several considerations 
should be assessed before conclusions are drawn, namely on the 
species selected for the study, type of tumors, correct definition of 
the endpoints and an appropriate statistical evaluation of tumor 
growth [240]. These steps should not be overlooked in order to 
provide consistent data regarding the biological activity against 
specific tumors in further human trials. If a compound has proven 
satisfactory results in animal models it can then be tested on 
humans. Although this is the final step in terms of trials for a 
compound to be readily available for the public it is also the most 
complicated step. The fact that the trials are carried out in humans 
requires extra caution in ethics and a well-designed procedure 
(doses, duration of treatment, concentration, placebos) to eliminate 
variables that would interfere in the real outcome of the treatment, 
moreover, it can be difficult to gather specific patients that suffer 
from the same type of cancer to have enough statistical 
significance. With all these drawbacks and pitfalls in anticancer 
treatment is there any hope against cancer? In terms of classic 
treatments with synthetic compounds, the evolution of technology 
will bring better and more effective therapeutics, so yes there 
should be hope. The awareness of the scientific community about 
the limitations and improvement areas in cancer therapy will surely 
overcome today’s limitations in the near future. Regarding natural 
compounds, namely phenolic compounds, and considering that only 
20% of the world’s plants have been investigated [241] it is 
legitimate to think that many more compounds will be discovered, 
and in those compounds, many anticancer molecules could be 
found. Hope can also come from other matrixes, like mushrooms, 
microbes and marine organisms which are now targets of intense 
research for chemopreventive and chemotherapeutic anticancer 
molecules [242, 243]. 
 Attending to the expected growing cases of cancer cases, 
research around this topic is also expected to increase, both on the 
mechanisms of cancer development and consequent methods to 
treat it. Funding for cancer research should be taken seriously, in 
order to reduce costs of treatments, patient suffering and mortality 
statistics. Mankind has come a long way in cancer therapy, but the 
road ahead is still full of challenges and opportunities.
CONFLICT OF INTEREST
 The authors declare that they have no conflict of interest 
regarding this manuscript.
ACKNOWLEDGEMENTS
 The authors are grateful to Fundação para a Ciência e a 
Tecnologia (FCT, Portugal) and COMPETE/QREN/EU for 
research project PTDC/AGR-ALI/110062/2009 and to CIMO 
(strategic project PEst-OE/AGR/UI0690/2011). 
REFERENCES
[1] Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. 
Global cancer statistics. CA. Cancer J. Clin., 2011, 61, 69-90.
[2] Schottenfeld, D.; Jr, J.F.F. Cancer epidemiology and prevention 3rd 
ed.; Oxford University Press: New York, 2006.
[3] Foo, J.; Michor, F. Evolution of resistance to anti-cancer therapy 
during general dosing schedules. J. Theor. Biol., 2010, 263, 179-
188. 
[4] Rocha, A.B.; Lopes, R.M.; Schwartsman, G. Natural products in 
anticancer therapy. Curr. Opin. Pharmacol., 2001, 1, 364-369.
[5] Gordaliza, M. Natural products as leads to anticancer drugs. Clin. 
Trans. Oncol., 2007, 9, 767-776.
[6] Bougard, F.; Gravot, A.; Milesi, S.; Gontier, E. Production of plant 
secondary metabolites: a historical perspective. Plant Sci., 2001,
161, 839-851.
[7] Crozier, A.; Clifford, M.N.; Ashihara, H. Plant secondary 
metabolites: occurrence, structure and role in the human diet; 
Blackwell Publishing: Oxford, 2006.
1252    Anti-Cancer Agents in Medicinal Chemistry, 2013, Vol. 13, No. 8 Carocho and Ferreira 
[8] Walton, N.J.; Brown, D.E. Chemicals from plants: perspectives on 
plant secondary products; Imperial College Press: London, 1999.
[9] Tansey, T.R.; Shechter, I. Structure and regulation of mammalian 
squalene synthase. Biochim. Biophys. Acta, 2000, 1529, 49-62.
[10] Dewick, P.M.; Medicinal natural products: a biosynthetic approach 
2nd ed.; John Wiley & Sons: West Sussex, 2002.
[11] Moss, G.P. Nomenclature of steroids. Pure Appl. Chem., 1989, 61, 
1783-1822.
[12] Roberts, M.F. Alkaloids: biochemistry, ecology and medicinal 
applications; Plenum Press: New York, 1998.
[13] Fraga, G.C.; Plant phenolics and human health: Biochemistry, 
nutrition and pharmacology; John Whiley & Sons: New Jersey, 
2010.
[14] Boudet, A. Evolution and current status of research in phenolic 
compounds. Phytochem., 2007, 68, 2722-2735.
[15] Lule, S.U.; Xia, W. Food phenolics, pros and cons: A review. Food 
Rev. Int., 2005, 21, 367-288.
[16] Dey, P.M.; Harborne, J.B. Plant biochemistry; Academic Press: 
California, 1997.
[17] Chung, K.; Wong, T.Y.; Wei, C.; Huang, Y.; Lin, Y. Tannins and 
human health: A review. Crit. Rev. Food Sci., 1998, 38, 421-464.
[18] Lüttge, U.; Beyschlag, W.; Büdel, B.; Francis, D. Progress in 
botany 72; Springer-Verlag: Heidelberg, 2011.
[19] Spencer, J.P.E. Flavonoids and related compounds: Bioavailability 
and function; CRC Press: Florida, 2012.
[20] Kalili, K.M.; Villiers, A. Recent development in the HPLC 
separation of phenolic compounds. J. Sep. Sci., 2011, 34, 854-876.
[21] Seigler, D.S. Plant secondary metabolism. Kluwer Academic Press, 
Massachussets: USA, 1998.
[22] Demirkiran, O. Xanthones in Hypericum: synthesis and biological 
activities. Top. Heterocycl. Chem., 2007, 9, 139-178.
[23] Nowakowska, Z. A review of the anti-infective and anti-
inflammatory chalcones. Eur. J. Med. Chem., 2007, 42, 125-137.
[24] Hopkins, W.G.; Hüner, N.P.A. Introduction to plant physiology. 
John Wiley & Sons, Inc.: New York, USA, 2004.
[25] Buranov, A. U.; Mazza, G. Lignin in straw of herbaceous crops. 
Ind. Crop. Prod., 2008, 28, 237-259.
[26] Yang, X.; Zhang, P.; Hu, L.; Zhang, M.; Liu, C.; Liu, H.; Zhou, Y. 
Synthesis and bioactivity evaluation of lignin related high-added-
value 1,4-dihydropyridines and polyhydroacridines. Ind. Crop. 
Prod., 2012, 38, 14-20.
[27] Sakagami, H.; Hashimoto, K.; Suzuki, F.; Ogiwara, T.; Satoh, K.; 
Ito, H.; Hatano, T.; Takashi, Y.; Fujisawa, S. Molecular 
requirements of lignin–carbohydrate complexes for expression of 
unique biological activities. Phytochem., 2005, 66, 2108-2120.
[28] Ayres, D.C.; Loike, J.D. Lignans: chemical, biological and clinical 
properties. Cambridge University Press: New York, USA, 1990.
[29] Topcu, G.; Demirkiran, O. Lignans from Taxus species. Top. 
Heterocycl. Chem., 2007, 11, 103-144.
[30] Lobo, A.M.; Lourenço, A.M. Biossíntese de produtos naturais; IST 
Press: Lisbon, 2007.
[31] Havsteen, B.H. The biochemistry and medical significance of the 
flavonoids. Farmacol. Therapeut., 2002, 96, 67-202.
[32] Aherne, S.A.; O’Brien, N.M. Dietary flavonols: chemistry, food 
content and metabolism. Nutrition, 2002, 18, 75-81.
[33] Si, D.; Wang, Y.; Zhou, Y.; Guo, Y.; Wang, J.; Zhou, H.; Li, Z.; 
Fawcett, J.P. Mechanism of CYP2C9 inhibition by flavones and 
flavonols. Drug Metab. Dispos., 2009, 37, 629-634.
[34] Martens, S.; Mithöfer, A. Flavones and flavone synthases. 
Phytochem., 2005, 66, 2399-2407.
[35] Aron, P.M.; Kennedy, J.A. Flavan-3-ols: nature, occurrence and 
biological activity. Mol. Nutr. Food Res., 2008, 52, 79-104.
[36] Andres, A.; Donovan, S.M.; Kuhlenschmidt, M.S. Soy isoflavones 
and virus infections. J. Nutr. Biochem., 2009, 20, 563-569.
[37] Messina, M.; Bennink, M. 10 Soyfoods, isoflavones and risk of 
colonic cancer: a review of the in vitro and in vivo data. Bailliere 
Clin. Endoc., 1998, 12, 707-728.
[38] Rostango, M.A.; Villares, A.; Guillamón, E.; García-Lafuente, A.; 
Martínez, J.A. Sample preparation for the analysis of isolflavones 
from soybeans and soy foods. J. Cromatogr. A, 2009, 1216, 2-29.
[39] Lanham-New, S.A.; Macdonald, I.A.; Roche, H.M. Nutrition and 
metabolism 2nd ed; John Wiley & Sons, West Sussex, 2011.
[40] Shi, L.; Feng, X.E.; Cui, J.R.; Fang, L.H.; Du, G.H.; Li, Q. S. 
Synthesis and biological activity of flavanone derivatives. Bioorg. 
Med. Chem. Lett., 2010, 20, 5466-5468.
[41] Tomás-Barberán, F.A.; Clifford, M.N. Flavanones, chalcones, and 
dihydrochalcones-nature, occurrence and dietary burden. J. Sci. 
Food Agric., 2000, 80, 1073-1080.
[42] Gould, K.; Davies, K.; Winefield C. Anthocyanins: biosynthesis, 
functions and applications; SpringerScience+Business Media, New 
York, 2009.
[43] Schofield, P.; Mbugua, D.M.; Pell, A.N. Analysis of condensed 
tannins: A review. Anim. Feed Sci. Technol., 2001, 91, 21-40.
[44] Castañeda-Ovando, A.; Pacheco-Hernández, M.L.; Páez-
Hernández, M.E.; Rodríguez, J.A., Galán-Vidal, C.A. Chemical 
studies of anthocyanins: a review. Food Chem., 2009, 113, 859-
871.
[45] Lila, M.A. Anthocyanins and human health: an in vitro
investigative approach. J. Biomed. Biotechnol., 2004, 2004, 306-
313. 
[46] Carocho, M.; Ferreira, I.C.F.R. A review on antioxidants, 
prooxidants and related controversy: natural and synthetic 
compounds, screening and analysis methodologies and future 
perspectives. Food Chem. Toxicol., 2013, 51, 15-25.
[47] Anand, P.; KunnumakaraB.; Sundaram, C.; Harikumar, K.B.; 
Tharakan, S.T.; Lai, O.S.; Sung, B.; Aggarwal, B.B. Cancer is a 
preventable disease that requires major lifestyle changes. Pharm. 
Res., 2008, 25, 2097-2116.
[48] Pan L.; Chai, H.; Kinghorn, A.D. The continuing search for 
antitumor agents from higher plants. Phytochem. Lett., 2010, 3, 1-8.
[49] Meng, X.; Zhong, J.; Liu, S.; Murray, M; Gonzalez-Angulo, A.M. 
A new hypothesis for the cancer mechanism. Cancer Metastasis 
Rev., 2012, 31, 247-268.
[50] Becsei-Kilborn, E. Scientific discovery and scientific reputation: 
The reception of Peyton Rous’ discovery of the chicken sarcoma 
virus. J. Hist. Biol., 2010, 43, 111-157.
[51] Sarid, R.; Gao, S. Viruses and human cancer: from detection to 
causality. Cancer Lett., 2011, 305, 218-227.
[52] Vähä-Koskela, M.J.V.; Heikkilä, J.E.; Hinkkanen, A.E. Oncolytic 
viruses in cancer therapy. Cancer Lett., 2007, 254, 178-216.
[53] Calin, G.A.; Croce, C.M. MicroRNAs and chromosomal 
abnormalities in cancer cells. Oncogene, 2006, 25, 6202-6210.
[54] Mitelman, F. Recurrent chromosome aberrations in cancer. Mutat. 
Res., 2000, 462, 247-253.
[55] Soto, A.M.; Sonnenschein, C. The somatic mutation theory of 
cancer: growing problems with the paradigm? Bioessays, 2004, 26, 
1097-1107.
[56] Frank, S.A.; Nowak, M.A. Problems of somatic mutation and 
cancer. Bioessays, 2004, 26, 291-299.
[57] Loeb, L.A.; Loeb, K.R.; Anderson, J.P. Multiple mutation in 
cancer. Proc. Natl. Acad. Sci., 2003, 776-781.
[58] Brunet, M. Cancer – a biological approach. Br. Med. J., 1957, 1, 
841-847.
[59] Thomas, L. Cellular and humoral aspects of the hypersensitive 
states. Heober-Harper, New York, 1957.
[60] Dunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schrieber, R.D. 
Cancer immunoediting: from immuno-surveillance to tumor 
escape. Nat. Immunol., 2002, 3, 991-998.
[61] Kim, R.; Emi, M.; Tanabe, K. Cancer immunoediting from imune 
surveillance to imune escape. Immunology, 2007, 121, 1-14.
[62] Haddow, A. Molecular repair, wound healing and carcinogenesis: 
Tumor production a possible overhealing? Adv. Cancer Res., 1972,
16, 181-234.
[63] Dvorak, H. Tumors: Wounds that do not heal: similarities between 
tumor stroma generation and wound healing. N. Engl. J. Med.,
1986, 315, 1650-1659.
[64] Riss, J.; Khanna, C.; Koo, S.; Chandramouli, G.V.R.; Yang, H.H.; 
Hu, Y.; Kleiner, D.E.; Rosenwald, A.; Schaefer, C.F.; Ben-Sasson, 
S.A.; Yang, L.; Powell, J.; Kane, D.W.; Star, R.A.; Aprelikova, O.; 
Bauer, K.; Vasselli, J.R.; Maranchi, J.K.; Kohn, K.W.; Buetow, 
K.H.; Linehan, W.M.; Weinstein, J.N.; Lee, M.P.; Klausner, R.D.; 
Barret, J.C. Cancers as wounds that do not heal: differences and 
similarities between renal regeneration/repair and renal cell 
carcinoma. Cancer Res., 2006, 66, 7216-7224.
The Role of Phenolic Compounds in the Fight against Cancer – A Review Anti-Cancer Agents in Medicinal Chemistry, 2013, Vol. 13, No. 8    1253 
[65] Cunningham, M.L. Role of increased DNA replication in the 
carcinogenic risk of nonmutagenic chemical carcinogens. Mutat. 
Res., 1996, 365, 59-69.
[66] Tennant, R.W. A perspective on nonmutagenic mechanisms in 
carcinogenesis. Environ. Health Persp., 1993, 101, 231-236.
[67] Sonnenschein, C.; Soto, A.M. Theories of carcinogenesis: an 
emerging perspective. Semin. Cancer. Biol., 2008, 18, 372-377.
[68] Sonnenschein, C.; Soto, A.M. Somatic mutation theory of 
carcinogenesis: why it should be dropped and replaced. Mol. 
Carcinog., 2000, 29, 205-211.
[69] Cao, Y.; Cao, R.; Bråkenhielm, E. Antiangiogenic mechanisms of 
diet-derived polyphenols. J. Nutr. Biochem., 2002, 13, 380-390.
[70] Madlener, S.; Illmer, C.; Horvath, Z.; Saiko, P.; Losert, A.; 
Herbacek, I.; Grusch, M.; Elford, H.L.; Krupitza, G.; Bernhaus, A.; 
Fritzer-Szekeres, M.; Szekeres, T. Gallic acid inhibits 
ribonucleotide reductase and cyclooxygenases in human HL-60 
promyelocytic leukemia cells. Cancer Lett., 2007, 245, 156-162.
[71] Reddy, T.C.; Reddy, D.B.; Aparna, A.; Arunasree, K.M.; Gupta, 
G.; Achari, C.; Reddy, G.V.; Lakshmipathi, V.; Subramanyam, A.; 
Reddanna, P. Anti-leukemic effects of gallic acid on human 
leukemia K562 cells: downregulation of COX-2, inhibition of 
BCR/ABL kinase and NF-kB inactivation. Toxicol. In Vitro, 2012,
26, 396-405.
[72] Lu, Y.; Jiang, F.; Jiang, H.; Wu, K.; Zheng, X.; Cai, Y.; 
Katakowski, M.; Chopp, M.; To, S.T. Gallic acid suppresses cell 
viability, proliferation, invasion and angiogenesis in human glioma 
cells. Eur. J. Pharmacol., 2010, 641, 102-107.
[73] Ji, B.; Hsu, W.; Yang, J.; Hsia, T.; Lu, C.; Chiang, J.; Yang, J.; Lin, 
C.; Lin, J.; Suen, L.; Wood, W.G.; Chung, J. Gallic acid induces 
apoptosis via caspase-3 and mitochondrion-dependent pathways in 
vitro and suppresses lung xenograft tumor growth in vivo. J. Agric. 
Food Chem., 2009, 57, 7596-7604.
[74] Umesalma, S.; Sudhandiran, G. Ellagic acid prevents rat colon 
carcinogenesis induced by 1, 2 dimethyl hydrazine through 
inhibition of AKT-phosphoinositide-3 kinase pathway. Eur. J. 
Pharmacol., 2011, 660, 249-258.
[75] Kim, S.; Gaber, M.W.; Zawaski, J.A.; Zhang, F.; Richardson, M.; 
Zhang, X.A.; Yang, Y. The inhibition of glioma growth in vitro and 
in vivo by a chitosan/ellagic acid composite biomaterial. 
Biomaterials, 2009, 30, 4743-4751.
[76] Alias, L.M.; Manoharan, S.; Vellaichammy, L.; Balakrishnan, S.; 
Ramachandran, C.R. Protective effect of Ferulic acid on 7,12-
dimethylbenz[a]anthracene-induced skin carcinogenesis in Swiss 
albino mice. Exp. Toxicol. Pathol., 2009, 61, 205-2014.
[77] Baskaran, N.; Manoharan, S.; Balakrishnan, S.; Pugalendhi, P. 
Chemopreventive potential of ferulic acid in 7,12-dimethylbenz[a] 
anthracene-induced mammary carcinogenesis in Sprague–Dawley 
rats. Eur. J. Pharmacol., 2010, 637, 22-29.
[78] Wang, C.; Chen, L.; Yang, L. Cuphiin D1, the macrocyclic 
hydrolyzable tannin induced apoptosis in HL-60 cell line. Cancer 
Lett., 2000, 149, 77-83.
[79] Miyamoto, K.; Nomura, M.; Sasakura, M.; Matsui, E.; Koshiura, 
R.; Murayama, T.; Furukawa, T.; Hatano, T.; Yoshida, T.; Okuda, 
T. Antitumor activity of oenothein B, a unique macrocyclic 
ellagitannin. Jpn. J. Cancer Res., 1993, 84, 99-103.
[80] Wang, C.; Chen, L.; Yang, L. Antitumor activity of four 
macrocyclic ellagitannins from Cuphea hyssopifolia. Cancer Lett.,
1999, 140, 195-200.
[81] Chen, J.; Shao, Y.; Huang, M.; Chin, C.; Ho, C. Inhibitory effect of 
caffeic acid phenethyl ester on human leukemia HL-60 cells. 
Cancer Lett., 1996, 108, 211-214.
[82] Kuo, H.; Kuo, W.; Lee, Y.; Lin, W.; Chou, F.; Tseng, T. Inhibitory 
effect of caffeic acid phenethyl ester on the growth of C6 glioma 
cells in vitro and in vivo. Cancer Lett., 2006, 234, 199-208.
[83] Lee, Y.; Kuo, H.; Chu, C.; Wang, C.; Lin, W.; Tseng, T. 
Involvement of tumor suppressor protein p53 and p38 MAPK in 
caffeic acid phenethyl ester-induced apoptosis of C6 glioma cells. 
Biochem. Pharmacol., 2003, 66, 2281-2289.
[84] Lin, W.; Liang, W.; Lee, Y.; Chuang, S.; Tseng, T. Antitumor 
progression potential of caffeic acid phenethyl ester involving 
p75NTR in C6 glioma cells. Chem. Biol. Interact., 2010, 188, 607-615.
[85] Ekmekcioglu, C.; Feyertag, J.; Marktl, W. Cinnamic acid inhibits 
proliferation and modulates brush border membrane enzyme 
activities in Caco-2 cells. Cancer Lett., 1998, 128, 137-144.
[86] Akao, Y.; Maruyama, H.; Matsumoto, K.; Ohguchi, K.; Nishizawa, 
K.; Sakamoto, T.; Araki, Y.; Mishima, S.; Nozawa, Y. Cell growth 
inhibitory effect of cinnamic acid derivatives from propolis on 
human tumor cell lines. Biol. Pharm. Bull., 2003, 26, 1057-1059.
[87] Revill, P.; Mealy, N.; Serradell.; Bolos, J.; Rosa, E. Panobinostat.
Drugs Fut., 2007, 32, 315-322.
[88] Ellis, L.; Pan, Y.; Smyth, G.K.; George, D.J.; McCormack, C.; 
Williams-Truax, R.; Mita, M.; Beck, J.; Burris, H.; Ryan, G.; 
Atadja, P.; Butterfoss, D.; Dugan, M.; Culver, K.; Johnstone, R.W.; 
Prince, H.M. Histone deacetylase inhibitor Panobinostat induces 
clinical responses with associated alterations in gene expression 
profiles in cutaneous T-cell lymphoma. Clin. Cancer Res., 2008,
14, 4500-4510.
[89] University of Utah; Novartis Pharmaceuticals. Pharmacokinetics 
and safety of Panobinostat in patients with advanced solid tumors 
and various degrees of hepatic function. In: Clinicaltrials.gov 
[Internet] 2009. [Cited 2012 Oct. 17] Available from: http:// 
clinicaltrials.gov/ct2/show/study/NCT01007968?term=Cinnamic+a
cid&rank=1 NLM Identifier: NCT01007968
[90] Devji, T.; Reddy, C.; Woo, C.; Awale, S.; Kadota, S.;  
Carrico-Moniz, D. Pancreatic anticancer activity of a novel 
geranylgeranylated coumarin derivative. Bioorg. Med. Chem. Lett.,
2011, 21, 5770-5773.
[91] Lopez-Gonzalez, J.S.; Prado-Garcia, H.; Aguilar-Cazares, D.; 
Molina-Guarneros, J.A.; Morales-Fuentes, J.; Mandoki, J.J. 
Apoptosis and cell cycle disturbances induced by coumarin and 7-
hydroxycoumarin on human lung carcinoma cell lines. Lung 
Cancer, 2004, 43, 275-283.
[92] Jung, J.; Lee, J.; Oh, S.; Lee, J.; Park, O. Synthesis and antitumor 
activity of 4-hydroxycoumarin derivatives. Bioorg. Med. Chem. 
Lett., 2004, 14, 5527-5531.
[93] Bronikowska, J.; Szliszka, E.; Jaworska, D.; Czuba, Z.P.; Krol, W. 
The coumarin psoralidin enhances anticancer effect of tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL). 
Molecules, 2012, 17, 6449-6464.
[94] Finn, G.J.; Creaven, B.S.; Egan, D.A. Daphnetin induced 
differentiation of human renal carcinoma cells and its mediation by 
p38 mitogen-activated protein kinase. Biochem. Farmacol., 2004,
67, 1779-1788.
[95] Watanabe, J.; Nishiyama, H.; Matsui, Y.; Ito, M.; Kawanishi, H.; 
Kamoto, T.; Ogawa, O. Dicoumarol potentiates cisplatin-induced 
apoptosis mediated by c-Jun N-terminal kinase in p53wild-type 
urogenital cancer cell lines. Oncogene, 2006, 25, 2500-2508.
[96] Matsui, Y.; Watanabe, J.; Ding, S.; Nishizawa, K.; Kajita, Y.; 
Ichioka, K.; Saito, R.; Kobayashi, T.; Ogawa, O.; Nishiyama, Y. 
Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 
wild-type urothelial cancer cells through p38 activation. BJU 
Intern., 2010, 105, 558-564.
[97] Yang, J.; Xiao, Y.; He, X.; Qiu, G.; Hu, X. Aesculetin-induced 
apoptosis through a ROS-mediated mitochondrial dysfunction 
pathway in human cervical cancer cells. J. Asian Nat. Prod. Res.,
2010, 12, 185-193.
[98] Thati, B.; Noble, A.; Creaven, B.S.; Walsh, M.; Kavanagh, K.; 
Egan, D.A. An in vitro investigation of the induction of apoptosis 
and modulation of cell cycle events in human cancer cells by 
bisphenanthroline-coumarin-6,7-dioxacetatocopper(II) complex. 
Chem. Biol. Interact., 2007, 168, 143-158.
[99] Lake, B.G. Coumarin metabolism, toxicity and carcinogenicity: 
relevance for human risk assessment. Food Chem. Toxicol., 1999,
37, 423-453. 
[100] Marshall, M.E.; Mendelsohn, L.; Butler, K.; Riley, L.; Cantrell, J.; 
Wiseman, C.; Taylor, R.; Macdonald, J.S. Treatment of metastatic 
renal cell carcinoma with coumarin (1,2-benzopyrone) and 
cimetidine: a pilot study. J. Clin. Oncol., 1987, 5, 862-866.
[101] Nolte, H.; Pedersen, L.; Mouridsen, H.T. Combined treatment of 
advanced malignant melanoma with coumarin and cimetidine. 
Anticancer Res., 1987, 7, 449-450.
[102] Jonsson Comprehensive Cancer Center; National Cancer Institute. 
Warfarin and Vatalanib in treating patients with advanced solid 
tumors. In: Clinicaltrials.gov [Internet] 2004. [Cited 2012 Dec. 1] 
Available from: http://www.clinicaltrials.gov/ct2/show/NCT00091299? 
term=warfarin+cancer&rank=2 NLM Identifier: NCT00091299
[103] Matsumoto, K.; Akao, Y.; Ohguchi, K.; Ito, T.; Tanaka, T.; Iinuma, 
M.; Nozawa, Y. Xanthones induce cell-cycle arrest and apoptosis 
1254    Anti-Cancer Agents in Medicinal Chemistry, 2013, Vol. 13, No. 8 Carocho and Ferreira 
in human colon cancer DLD-1 cells. Bioorg. Med. Chem., 2005,
13, 6064-6069.
[104] Nakagawa, Y.; IInuma, M.; Naoe, T.; Nozawa, Y.; Akao, Y. 
Characterized mechanism of a-mangostin-induced cell death: 
caspase-independent apoptosis with release of endonuclease-G 
from mitochondria and increased miR-143 expression in human 
colorectal cancer DLD-1 cells. Bioorg. Med. Chem., 2007, 15, 
5620-5628.
[105] Akao, Y.; Nakagawa, Y.; Iinuma, M.; Nozawa, Y. Anti-cancer 
effects of xanthones from pericarps of mangosteen. Int. J. Mol. Sci.,
2008, 9, 355-370.
[106] Matsumoto, K.; Akao, Y.; Yi, H.; Ohguchi, K.; Ito, T.; Tanaka, T.; 
Kobayashi, E.; Iinuma, M.; Nozawa, Y. Preferential target is 
mitochondria in a-mangostin-induced apoptosis in human leukemia 
HL60 cells. Bioorg. Med. Chem., 2004, 12, 5799-5806.
[107] Wang, J.J.; Sanderson, B.J.S.; Zhang, W. Cytotoxic effect of 
xanthones from pericarp of the tropical fruit mangosteen (Garcinia 
mangostana Linn.) on human melanoma cells. Food Chem. 
Toxicol., 2011, 49, 2385-2391.
[108] Kaomongkolgit, R.; Chaisomboon, N.; Pavasant, P. Apoptotic 
effect of alpha-mangostin on head and neck squamous carcinoma 
cells. Arch. Oral Biol., 2011, 56, 483, 490.
[109] Chao, A.; Hsu, Y.; Liu, C.; Kuo, P. -mangostin, a dietary 
xanthone, induces autophagic cell death by activating the AMP-
activated protein kinase pathway in glioblastoma cells. J. Agric. 
Food Chem., 2011, 59, 2086-2096.
[110] Shan, T.; Ma, Q.; Guo, K.; Liu, J.; Li, W.; Wang, F.; Wu, E. 
Xanthones from mangosteen extracts as natural chemopreventive 
agents: potential anticancer drugs. Curr. Mol. Med., 2011, 11, 666-
677.
[111] Ho, C.; Huang, Y.; Chen, C. Garcinone E, a xanthone derivative, 
has potent cytotoxic effect against hepatocellular carcinoma cell 
lines. Planta Med., 2002, 68, 975-979.
[112] Hahnvajanawong, C.; Boonyanugomol, W.; Nasomyon, T.; 
Loilome, W.; Namwat, N.; Anantachoke, N.; Tassaneeyakul, W.; 
Sripa, B.; Namwat, W.; Reutrakul, V. Apoptotic activity of caged 
xanthones from Garcinia hanburyi in cholangiocarcinoma cell 
lines. World J. Gastroenterol., 2010, 16, 2235-2243.
[113] Na, Y. Recent cancer drug development with xanthone structures. 
J. Pharm. Pharmacol., 2009, 61, 707-712.
[114] Korobi, M.; Shinmoto, H.; Tsushida, T.; Shinohara, K. Phloretin-
induced apoptosis in B 16 melanoma 4A5 cells by inhibition of 
glucose transmembrane transport. Cancer Lett., 1997, 19, 207-212.
[115] Yang, K.; Tsai, C.; Wang, Y.; Wei, P.; Lee, C.; Chen, J.; Wu, C.; 
Ho, Y. Apple polyphenol phloretin potentiates the anticancer 
actions of Paclitaxel through induction of apoptosis in human Hep 
G2 cells. Mol. Carcinog., 2009, 48, 420-431.
[116] Cheng, S.; Liu, R.H.; Sheu, J.; Chen, S.; Sinchaikul, S.; Tsay, G.J. 
Toxicogenomics of A375 human malignant melanoma cells treated 
with arbutin. J. Biomed. Sci., 2007, 14, 87-105.
[117] Szliszka, E.; Czuba, Z.P.; Mazur, B.; Paradysz, A.; Krol, W. 
Chalcones and dihydrochalcones augment TRAIL-mediated 
apoptosis in prostate cancer cells. Molecules, 2010, 15, 5336-5353.
[118] Anto, R.J.; Sukumaran, K.; Kuttan, G.; Rao, M.N.A.; Subbaraju, 
V.; Kuttan, R. Anticancer and antioxidant activity of synthetic 
chalcones and related compounds. Cancer Lett., 1995, 97, 33-37.
[119] Boumendjel, A.; Boccard, J.; Carrupt, P.; Nicolle, E.; Blanc, M.; 
Geze, A.; Choisnard, L.; Wouessidjewe, D.; Matera, E.; Dumontet, 
C. Antimitotic and antiproliferative activities of chalcones: forward 
structure–activity relationship. J. Med. Chem., 2008, 51, 2307-
2310.
[120] Kumar, D.; Kuman, N.M.; Akamatsu, K.; Kusaka, E.; Harada, H.; 
Ito, T. Synthesis and biological evaluation of indolyl chalcones as 
antitumor agents. Bioorg. Med. Chem. Lett., 2010, 20, 3916-3919.
[121] Mohamed, M.F.; Mohamed, M.S.; Shouman, S.A.; Fathi, M.M.; 
Abdelhamid, I.A. Synthesis and biological evaluation of a novel 
series of chalcones incorporated pyrazole moiety as anticancer and 
antimicrobial agents. Appl. Biochem. Biotechnol., 2012, 168, 1153-
1162.
[122] Orlikova, B.; Tasdemir, D.; Golais, F.; Dicato, M.; Diederich, M. 
Dietary chalcones with chemopreventive and chemotherapeutic 
potential. Genes Nutr., 2011, 6, 125-147.
[123] Jang, M.; Cai, L.; Udeani, G.O.; Slowing, K.V.; Thomas, C.F.; 
Beecher, C.W.W.; Fong, H.H.S.; Farnsworth, N.R.; Kinghorn, 
A.D.; Mehta, R.G.; Moon, R.C.; Pezzuto, J.M. Cancer 
chemopreventive activity of resveratrol, a natural product derived 
from grapes. Science, 1997, 275, 218-220.
[124] Hagiwara, K.; Kosaka, N.; Yoshioka, Y.; Takahashi, R.; Takeshita, 
F.; Ochiya, T. Stilbene derivatives promote Ago2-dependent 
tumour-suppressive microRNA activity. Sci. Rep., 2012, 2, 
doi:10.1038/srep00314
[125] Simoni, D.; Roberti, M.; Invidiata, F.P.; Aiello, E.; Aiello, S.; 
Marchetti, P.; Baruchello, R.; Eleopra, M.; Cristina, A.D.; 
Grimaudo, S.; Gebbia, N.; Crosta, L.; Dieli, F.; Tolomeo, M. 
Stilbene-based anticancer agents: resveratrol analogues active 
toward HL60 leukemic cells with a non-specific phase mechanism. 
Bioorg. Med. Chem. Lett., 2006, 16, 3245-3248.
[126] Fulda, S.; Debatin, K. Sensitization for anticancer drug-induced 
apoptosis by the chemopreventive agent resveratrol. Oncogene,
2004, 23, 6702-6711.
[127] University of Wisconsin, Madison. A biological study of 
resveratrol's effects on Notch-1 signaling in subjects with low 
grade gastrointestinal tumors. In: Clinicaltrials.gov [Internet] 2011. 
[Cited 2012 Dec. 2] Available from: http://www.clinicaltrials.gov/ 
ct2/show/NCT01476592?term=resveratrol&rank=22 NLM 
Identifier: NCT01476592
[128] University of Michigan Cancer Center; National Cancer Institute. 
Resveratrol in treating patients with colorectal cancer that can be 
removed by surgery. In: Clinicaltrials.gov [Internet] 2007. [Cited 
2012 Dec. 2] Available from: http://www.clinicaltrials.gov/ct2/ 
show/NCT00433576?term=resveratrol&rank=39 NLM Identifier: 
NCT00433576
[129] University of Michigan Cancer Center; National Cancer Institute. 
UMCC 2003-064 Resveratrol in preventing cancer in healthy 
participants (IRB 2004-535). In: Clinicaltrials.gov [Internet] 2004. 
[Cited 2012 Dec. 2] Available from: http://www.clinicaltrials. 
gov/ct2/show/NCT00098969?term=resveratrol&rank=41 NLM 
Identifier: NCT00098969
[130] Aggarwal, B.B.; Bhardwaj, A.; Aggarwal, R.; Seeram, N.P.; 
Shishodia, S.; Takada, Y. Role of resveratrol in prevention and 
therapy of cancer: preclinical and clinical studies. Anticancer Res.,
2004, 24, 2783-2840.
[131] Signorelli, P.; Ghidoni, R. Resveratrol as an anticancer nutrient: 
molecular basis, open questions and promises. J. Nutr. Biochem., 
2005, 16, 449-466.
[132] Athar, M.; Back, J.H.; Tang, X.; Kim, K.H.; Kopelovich L.; 
Bickers, D.R.; Kim, A L. Resveratrol: a review of preclinical 
studies for human cancer prevention. Toxicol. Appl. Pharmacol.,
2007, 224, 274-283.
[133] Remsber, C.M.; Yáñez, J.A.; Ogami, Y.; Vega-Villa, K.R.; 
Rimando, A.M.; Davies, N.M. Pharmacometrics of pterostilbene: 
preclinical pharmacokinetics and metabolism, anticancer, 
antiinflammatory, antioxidant and analgesic activity. Phytother. 
Res., 2007, 22, 169-179.
[134] Piotrowska, H.; Kucinska, M.; Murias, M. Biological activity of 
piceatannol: leaving the shadow of resveratrol. Mutat. Res.-Rev. 
Mutat., 2012, 750, 60-82.
[135] Chowdhury, S.A.; Kishino, K.; Satoh, R.; Hashimoto, K.; Kikuchi, 
H.; Nishiwaka, H.; Shirataki, Y.; Sakagami, H. Tumor-specificity 
and apoptosis-inducing activity of stilbenes and flavonoids. 
Anticancer Res., 2005, 25, 2055-2064.
[136] Lee, E.; Min, H.; Park, H. J.; Chung, H.; Kim, S.; Han, Y.N.; Lee, 
S.K. G2/M cell cycle arrest and induction of apoptosis by a 
stilbenoid, 3,4,5-trimethoxy-4V-bromo-cis-stilbene, in human lung 
cancer cells. Life Sci., 2004, 75, 2829-2839.
[137] Osmond, G.W.; Masko, E.M.; Tyler, D.S.; Freedland, S.J.; Pizzo, 
S. In vitro and in vivo evaluation of resveratrol and 3,5-dihydroxy-
4’-acetoxy-trans-stilbene in the treatment of human prostate 
carcinoma and melanoma. J. Surg. Res., 2013, 179, 141-148.
[138] Koiková, B.; Slameová, D.; Mikuláová, M.; Horváthová, E.; 
Lábaj, J. Reduction of carcinogenesis by bio-based lignin 
derivatives. Biomass Bioenerg., 2002, 23, 153-159.
[139] Thompson, L.U. Experimental studies on lignans and cancer. 
Bailliere Clin. Endoc., 1998, 12, 691-705.
[140] Park, B.; Oh, S.; Ahn, K.; Kwon, O.; Lee, H. (–)-Syringaresinol 
inhibits proliferation of human promyelocytic HL-60 leukemia 
cells via G1 arrest and apoptosis. Int. Immunopharmacol., 2008, 8, 
967-973.
The Role of Phenolic Compounds in the Fight against Cancer – A Review Anti-Cancer Agents in Medicinal Chemistry, 2013, Vol. 13, No. 8    1255 
[141] Bylund, A.; Saarinen, N.; Zhang, J.; Bergh, A.; Widmark, A.; 
Johansson, A.; Lundin, E.; Adlercreutz, H.; Hallmans, G.; Stattin, 
P.; Mäkela, S. Anticancer effects of a plant lignan 7-
Hydroxymatairesinol on a prostate cancer. Exp. Biol. Med., 2005,
230, 217-223.
[142] Giri, A.; Narasu, M.L. Production of podophyllotoxin from 
Podophyllum hexandrum: a potential natural product for clinically 
useful anticancer drugs. Cytotechnology, 2000, 34, 17-26.
[143] Greenwald, R.B.; Conover, C.D.; Pendri, A.; Choe, Y.H.; Martinez, 
A.; Wu, D.; Guan, S.; Yao, Z.; Shum, K.L. Drug delivery of 
anticancer agents: water soluble 4-poly (ethylene glycol) 
derivatives of the lignan, podophyllotoxin. J. Control Release,
1999, 61, 281-294.
[144] Mustafa, J.; Khan, S.I.; Ma, G.; Walker, L.A.; Khan, I.A. Synthesis 
and anticancer activities of fatty acid analogs of podophyllotoxin. 
Lipids, 2004, 39, 167-172.
[145] University of Pittsburg; Novartis Pharmaceuticals. Carboplatin and 
Etoposide plus LBH589 for small cell lung cancer. In: 
Clinicaltrials.gov [Internet] 2009. [Cited 2012 Dec. 5] Available 
from: http://www.clinicaltrials.gov/ct2/show/NCT00958022?term= 
podophyllotoxin&rank=6 NLM Identifier: NCT00958022
[146] Northwestern University; National Cancer Institute. Doxorubicin 
hydrochloride liposome and rituximab with combination 
chemotherapy in treating patients with newly diagnosed Burkitt's 
lymphoma or Burkitt-like lymphoma. In: Clinicaltrials.gov 
[Internet] 2006. [Cited 2012 Dec.5] Available from: http://www. 
clinicaltrials.gov/ct2/show/NCT00392990?term=podophyllotoxin&
rank=5 NNLM Identifier: NCT00392990
[147] City of Hope Medical Center. Busulfan, Etoposide, and intensity-
modulated radiation therapy followed by donor stem cell transplant 
in treating patients with advanced myeloid cancer. In: 
Clinicaltrials.gov [Internet] 2007. [Cited 2012 Dec. 5] Available 
from: http://www.clinicaltrials.gov/ct2/show/NCT00540995?term= 
podophyllotoxin&rank=4 NLM Identifier: NCT00540995 
[148] Case Comprehensive Cancer Center. Bortezomib, Mitoxantrone, 
Etoposide, and Cytarabine in relapsed or refractory acute myeloid 
leukemia. In: Clinicaltrials.gov [Internet] 2010. [Cited 2012 Dec. 5] 
Available from: 
http://www.clinicaltrials.gov/ct2/show/NCT01127009?term=podop
hyllotoxin&rank=1 NLM Identifier: NCT01127009
[149] Landete, J.M. Plant and mammalian lignans: A review of source, 
intake, metabolism, intestinal bacteria and health. Food Res. Int.,
2012, 46, 410-424.
[150] Wei, Y.; Zhao, X.; Kariya, Y.; Fukata, H.; Teshigawara, K.; 
Uchida, A. Induction of apoptosis by quercetin: involvement of 
heat shock protein. Cancer Res., 1994, 54, 4952-4957.
[151] Tan, W.; Lin, L.; Li, M.; Zhang, Y.; Tong, Y.; Xiao, D.; Ding, J. 
Quercetin, a dietary-derived flavonoid, possesses antiangiogenic 
potential. Eur. J. Pharmacol., 2003, 459, 255-262.
[152] Nair, H.; Rao, K.V.K.; Aalinkeel, R.; Mahajan, S.; Chawda,  
R.; Schwartz, S.A. Inhibition of prostate cancer cell colony 
formation by the flavonoid quercetin correlates with modulation of 
specific regulatory genes. Clin. Diagn. Lab. Immunol., 2004, 11, 
63-69.
[153] Zhang, H.; Zhang, M.; Yu, L.; Zhao, Y.; He, N.; Yang, X. 
Antitumor activities of quercetin and quercetin-50,8-disulfonate in 
human colon and breast cancer cell lines. Food Chem. Toxicol.,
2012, 50, 1589-1599.
[154] Tan, J.; Wang, B.; Zhu, L. DNA binding and oxidative DNA 
damage induced by a quercetin copper(II) complex: potential 
mechanism of its antitumor properties. J. Biol. Inorg. Chem., 2009,
14, 727-739.
[155] Tan, J.; Wang, B.; Zhu, L. DNA binding, cytotoxicity, apoptotic 
inducing activity, and molecular modeling study of quercetin 
zinc(II) complex. Bioorg. Chem., 2009, 17, 614-620.
[156] Yuan, Z.; Chen, L.; Fan, L.; Tang, M.; Yang, G.; Yang, H.; Du, X.; 
Wang, G.; Yao, W.; Zhao, Q.; Ye, B.; Wang, R.; Diao, P.; Zhang, 
W.; Wu, H.; Zhao, X.; Wei, Y. Liposomal quercetin efficiently 
suppresses growth of solid tumors in murine models. Clin. Cancer 
Res., 2006, 12, 3193-3199.
[157] Ferry, D.R.; Smith, A.; Malkhandi, J.; Fyfe, D.W.; Takats, P.G.; 
Anderson, D.; Baker, J.; Kerr, D.J. Phase I clinical trial of the 
flavonoid quercetin: pharmacokinetics and evidence for in vivo
tyrosine kinase inhibitor. Clin. Cancer Res., 1996, 2, 659-668.
[158] Mulholland, P.J.; Ferry, D.R.; Anderson, D.; Hussain, S.A.; Young, 
A.M.; Cook, J.E.; Hodgkin, E.; Seymour, L.W.; Kerr, D.J. Pre-
clinical and clinical study of QC12, a water-soluble, pro-drug of 
quercetin. Ann. Oncol., 2001, 12, 245-148.
[159] Mylonis, I.; Lakka, A.; Tsakalof, A.; Simos, G. The dietary 
flavonoid kaempferol effectively inhibits HIF-1 activity and 
hepatoma cancer cell viability under hypoxic conditions. Biochem. 
Biophys. Res. Commun., 2010, 398, 74-78.
[160] Zhang, Y.; Chen, A. Y.; Li, M.; Chen, C.; Yao, Q. Ginkgo biloba
extract kaempferol inhibits cell proliferation and induces apoptosis 
in pancreatic cancer cells. J. Surg. Res., 2008, 148, 17-23.
[161] Yoshida, T.; Konishi, M.; Horinaka, M.; Yasuda, T.; Goda, A.E.; 
Taniguchi, H.; Yano, K.; Wakada, M.; Sakai, T. Kaempferol 
sensitizes colon cancer cells to TRAIL-induced apoptosis. 
Biochem. Biophys. Res. Commun., 2008, 375, 129-133.
[162] Huang, W.; Chiu, Y.; Fan, M.; Lu, H.; Yeh, H.; Li, K.; Chen, P.; 
Chung, J.; Yang, J. Kaempferol induced apoptosis via endoplasmic 
reticulum stress and mitochondria-dependent pathway in  
human osteosarcoma U-2 OS cells. Mol. Nutr. Food Res., 2010, 54, 
1585-1595.
[163] Woo, K.J.; Jeong, Y.; Park, J.; Kwon, T. Chrysin-induced apoptosis 
is mediated through caspase activation and Akt inactivation in 
U937 leukemia cells. Biochem. Biophys. Res. Commun., 2004, 325, 
1215-1222.
[164] Li, X.; Wang, J.; Huang, J.; Xiong, X.; Chen, M.; Ong, C.; Shen, 
H.; Yang, X. Chrysin promotes tumor necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL) induced apoptosis in human 
cancer cell lines. Toxicol. In Vitro, 2011, 25, 630-635.
[165] Khan, M.S.; Devaraj, H.; Devaraj, N. Chrysin abrogates early 
hepatocarcinogenesis and induces apoptosis in N-nitrosodiethylamine-
induced preneoplastic nodules in rats. Toxicol. Appl. Pharmacol.,
2011, 251, 85-94.
[166] Glory, M.D.; Thiruvengadam, D. Potential chemopreventive role of 
chrysin against N-nitrosodiethylamine-induced hepatocellular 
carcinoma in rats. Biomed. Prev. Nutr., 2012, 2, 106-112.
[167] Drees, M.; Dengler, W.A.; Roth,T.; Labonte, H.; Mayo, J.; 
Malspeis, L.; Grever, M.; Sausville,E.A.; Fiebig, H.H. Flavopiridol 
(L86-8275): selective antitumor activity in vitro and activity in vivo
for prostate carcinoma cells. Clin. Cancer Res., 1997, 3, 273-279.
[168] Wenzel, U.; Kuntz, S.; Brendel, M.D.; Daniel, H. Dietary flavone 
is a potent apoptosis inducer in human colon carcinoma cells. 
Cancer Res., 2000, 60, 3823-3831.
[169] Tundis, R.; Deguin, B.; Loizzo, M.R.; Bonesi, M.; Statti, G.A.; 
Tillequin, F.; Menichini, F. Potential antitumor agents: flavones 
and their derivatives from Linaria reflexa Desf. Bioorg. Med. 
Chem. Lett., 2005, 15, 4757-4760.
[170] Lv, P.; Wang, K.; Li, Q.; Chen, J.; Sun, J.; Zhu, H. Design, 
synthesis and biological evaluation of chrysin long-chain 
derivatives as potential anticancer agents. Bioorg. Med. Chem.,
2010, 18, 1117-1123.
[171] Corbett, T.H.; Bissery, M.; Wozniak, A.; Plowman, J.; Polin, L.; 
Tapazoglou, E.; Dieckman, J.; Valeriote, F. Activity of flavone 
acetic acid (NSC-347512) against solid tumors of mice. Invest. 
New Drugs, 1986, 4, 207-220.
[172] Evelhoch, J.L.; Bissery, M.; Chabot, G.G.; Simpson, N.E.; McCoy, 
C.L.; Heilbrun, L.K.; Corbett, T.H. Flavone acetic acid (NSC 
347512)-induced modulation of murine tumor physiology 
monitored by in vivo nuclear magnetic resonance spectroscopy. 
Cancer Res., 1988, 48, 4749-4755.
[173] Kerr, D.J.; Maughan, T.; Newlands, E.; Rustin, G.; Bleehen, N.M.; 
Lewis, C.; Kaye, S.B. Phase II trials of flavone acetic acid in 
advanced malignant melanoma and colorectal carcinoma. Br. J. 
Cancer, 1989, 60, 104-106.
[174] Bibby, M.C. Flavone acetic acid - an interesting novel therapeutic 
agent or just another disappointment? Br. J. Cancer, 1991, 63,  
3-5.
[175] Kitson, R.P.; Ohashi, M.; Brunson, K.W.; Goldfarb, R.H. Flavone 
acetic acid enhances accumulation of IL-2 activated NK cells 
within established metastases. In Vivo, 1998, 6, 593-597.
[176] Panaro, N.J.; Popescu, N.C.; Harris, S.R.; Thorgeirsson, U.P. 
Flavone acetic acid induces a G2/M cell cycle arrest in mammary 
carcinoma cells. Br. J. Cancer, 1999, 80, 1905-1911.
[177] Joshi, K.S.; Rathos, M.J.; Mahajan, P.; Wagh, V.; Shenoy, S.; 
Bhatia, D.; Chile, S.; Sivakumar, M.; Maier, A.; Fiebig, H.; 
1256    Anti-Cancer Agents in Medicinal Chemistry, 2013, Vol. 13, No. 8 Carocho and Ferreira 
Sharma, S. P276-00, a novel cyclin-dependent inhibitor induces 
G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells 
and significant in vivo efficacy in tumor models. Mol. Cancer 
Ther., 2007, 6, 926-934.
[178] Piramal Healthcare Limited. A clinical trial comparing 
Gemcitabine and Carboplatin with and without P276-00 in subjects 
with metastatic triple negative breast cancer, with a run-in of 
escalating dose of P276-00 added to Gemcitabine and Carboplatin. In: 
Clinicaltrials.gov [Internet] 2011. [Cited 2012 Oct. 23] Available 
from: http://clinicaltrials.gov/ct2/show/record/NCT01333137?term= 
flavone&rank=1 NLM Identifier: NCT01333137
[179] Menon, L.G.; Kuttan, R.; Kuttan, G. Anti-metastatic activity of 
curcumin and catechin. Cancer Lett., 1999, 141, 159-165.
[180] Al-Hazzani, A.; Alshatwi, A.A. Catechin hydrate inhibits 
proliferation and mediates apoptosis of SiHa human cervical cancer 
cells. Food Chem. Toxicol., 2011, 49, 3281-3286.
[181] Farivar-Mohseni, H.; Kandzari, S.J.; Zaslau, S.; Riggs, D.R.; 
Jackson, B.J.; McFadden, D.W. Synergistic effects of Cox-1 and -2 
inhibition on bladder and prostate cancer in vitro. Am. J. Surg.,
2004, 188, 505-510.
[182] McMillian, B.; Riggs, D.R.; Jackson, B.J.; Cunningham, C.; 
McFadden, D.W. Dietary influence on pancreatic cancer growth by 
catechin and inositol hexaphosphate. J. Surg. Res., 2007, 141, 115-
119.
[183] Vittorio, O.; Cirillo, G.; Iemma, F.; Di Turi, G.; Jacchetti, E.; 
Curcio, M.; Barbuti, S.; Funel, N.; Parisi, O.I.; Picci, N. Dextran-
catechin conjugate: a potential treatment against the pancreatic 
ductal adenocarcinoma. Pharm. Res., 2012, 29, 2601-2614.
[184] University of Arizona; National Cancer Institute. Green tea extract 
(Polyphenon E) in preventing cancer in healthy participants. In: 
Clinicaltrials.gov [Internet] 2004. [Cited 2012 Oct. 25] Available 
from: http://clinicaltrials.gov/ct2/show/NCT00091325?term=catechin& 
rank=33 NLM Identifier: NCT00091325
[185] National Cancer Institute; University of Arizona. Green tea extract 
in preventing cervical cancer in patients with human 
papillomavirus and low-grade cervical intraepithelial neoplasia. In: 
Clinicaltrials.gov [Internet] 2006. [Cited 2012 Oct. 25] Available 
from: 
http://clinicaltrials.gov/ct2/show/NCT00303823?term=catechin&ra
nk=32 NLM Identifier: NCT00303823
[186] M.D. Anderson Cancer Center; National Cancer Institute. Green 
tea extract in preventing esophageal cancer in patients with 
Barrett's esophagus. In: Clinicaltrials.gov [Internet] 2005. [Cited 
2012 Oct. 25] Available from: http://clinicaltrials.gov/ct2/show/ 
NCT00233935?term=catechin&rank=39 NLM Identifier: 
NCT00233935 
[187] University of Wisconsin, Madison; National Cancer Institute. 
Green tea extract in treating patients with nonmetastatic bladder 
cancer. In: Clinicaltrials.gov [Internet] 2008. [Cited 2012 Oct. 25] 
Available from: http://clinicaltrials.gov/ct2/show/NCT00666562? 
term=catechin&rank=22 NLM Identifier: NCT00666562
[188] National Cancer Institute; Univeristy of Arizona. Defined green tea 
catechins in treating patients with prostate cancer undergoing 
surgery to remove the prostate. In: Clinicaltrials.gov [Internet] 
2008. [Cited 2012 Oct. 25] Available from: http://clinicaltrials. 
gov/ct2/show/record/NCT00459407?term=catechin&rank=14 
NLM Identifier: NCT00459407
[189] Case Comprehensive Cancer Center; National Cancer Institute. 
Defined green tea catechin extract in treating patients with 
localized prostate cancer undergoing surgery. In: Clinicaltrials.gov 
[Internet] 2011. [Cited 2012 Oct. 25] Available from: 
http://clinicaltrials.gov/ct2/show/record/NCT01340599?term=catec
hin&rank=5 NLM Identifier: NCT01340599
[190] Mayo Clinic; National Cancer Institute. Polyphenon E in treating 
patients with high-risk of colorectal cancer. In: Clinicaltrials.gov 
[Internet] 2012. [Cited 2012 Oct. 25] Available from: 
http://clinicaltrials.gov/ct2/show/NCT01606124?term=catechin&ra
nk=23 NLM Identifier: NCT01606124
[191] Lung, H.L.; Ip, W.K.; Wong, C.K.; Mak, N.K.; Chen, Z.Y.; Leung, 
K.N. Anti-proliferative and differentiation-inducing activities of the 
green tea catechin epigallocatechin-3-gallate (EGCG) on the 
human eosinophilic leukemia EoL-1 cell line. Life Sci., 2002, 72, 
257-268. 
[192] Magyar, J. É.; Gamberucci, A.; Konta, L.; Margittai, É.; Mandl, J.; 
Bánhehyi G.; Benedetti, A.; Csala, M. Endoplasmic reticulum 
stress underlying the pro-apoptotic effect of epigallocatechin 
gallate in mouse hepatoma cells. Int. J. Biochem. Cell Biol., 2009,
41, 694-700.
[193] Ellis, L.Z.; Liu, W.; Luo, Y.; Okamoto, M.; Qu, D.; Dunn, J.H.; 
Fujita, M. Green tea polyphenol epigallocatechin-3-gallate 
suppresses melanoma growth by inhibiting inflammasome and IL-
1 secretion. Biochem. Biophys. Res. Commun., 2011, 414, 551-
556.
[194] Matsumura, K.; Kaihatsu, K.; Mori, S.; Cho, H.H.; Kato, N.; Hyon, 
S.H. Enhanced antitumor activities of (-)-epigallocatechin-3-O-
gallate fatty acid monoester derivatives in vitro and in vivo.
Biochem. Biophys. Res. Commun., 2008, 377, 1118-1122.
[195] Singh, B.N.; Shankar, S.; Srivastava, R.K. Green tea catechin, 
epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and 
clinical applications. Biochem. Pharmacol., 2011, 82, 1807-1821.
[196] Martin-Luther-Universität Halle-Wittenberg; University of Ulm; 
Koordinierungszentrum für Klinische Studien Halle; Deutsche 
Krebshilfe e.V., Bonn (Germany). Minimizing the risk of 
metachronous adenomas of the colorectum with green tea extract -
MIRACLE-. In: Clinicaltrials.gov [Internet] 2011. [Cited 2012 Oct. 25] 
Available from: http://clinicaltrials.gov/ct2/show/NCT01360320? 
term=epigallocatechin&rank=17 NLM Identifier: NCT01360320 
[197] University of Minnesota - Clinical and Translational Science Institute. 
Green tea and reduction of breast cancer risk. In: Clinicaltrials.gov 
[Internet] 2009. [Cited 2012 Oct. 25] Available from: http:// 
clinicaltrials.gov/ct2/show/NCT00917735?term=epigallocatechin&
rank=24 NML Identifier: NCT00917735 
[198] Shandong Cancer Hospital and Institute. Oral green tea extract for 
small cell lung cancer. In: Clinicaltrials.gov [Internet] 2011. [Cited 
2012 Oct. 25] Available from: http://clinicaltrials.gov/ct2/show/ 
NCT01317953?term=epigallocatechin&rank=13 NML Identifier: 
NCT01317953 
[199] Suzuki, K.; Koike, H.; Matsui, H.; Ono, Y.; Hasumi, M.; Nakazato, 
H.; Okugi, H.; Sekine, Y.; Oki, K.; Ito, K.; Yamamoto, T.; 
Fukabori, Y.; Kurokawa, K.; Yamanaka, H. Genistein, a soy 
isoflavone, induces glutathione peroxidase in the human prostate 
cancer cell lines LNCAP and PC-3. Int. J. Cancer, 2002, 99, 846-
852.
[200] Wang, J.; Eltoum, I.; Lamartiniere, C.A. Dietary genistein 
suppresses chemically induced prostate cancer in Lobund–Wistar 
rats. Cancer Lett., 2002, 186, 11-18.
[201] Banerjee, S.; Zhang, Y.; Ali, S.; Bhuiyan, M.; Wang, Z.; Chiao, 
P.J.; Philip, P.A.; Abbruzzese, J.; Sarkar, F.H. Molecular evidence 
for increased antitumor activity of gemcitabine by genistein in vitro
and in vivo using an orthotopic model of pancreatic cancer. Cancer 
Res., 2005, 65, 9064-9072.
[202] Mohammad, R.M.; Banerjee, S.; Li, Y.; Aboukameel, A.; Kucuk, 
O.; Sarkar, F.H. Cisplatin-induced antitumor activity is potentiated 
by the soy isoflavone genistein in BxPC-3 pancreatic tumor 
xenografts. Cancer, 2006, 106, 1260-1268.
[203] Yanhong, H.; Peng, Y.; Qinghong, Z.; Xiaoyan, X. Genistein 
sensitizes ovarian carcinoma cells to chemotherapy by switching 
the cell cycle progression in vitro. J. Med. Coll. PLA, 2009, 24, 
125-135.
[204] Sahin, K.; Tuzcu, M.; Basak, N.; Caglayan, B.; Kilic, U.; Sahin, F.; 
Kucuk, O. Sensitization of cervical cancer cells to cisplatin by 
genistein: the role of NFB and Akt/mTOR signaling pathways. J. 
Oncol., 2012, 2012, 1-6.
[205] Siegelin, M.D.; Siegelin, Y.; Habel, A.; Gaiser, T. Genistein 
enhances proteasomal degradation of the short isoform of FLIP in 
malignant glioma cells and thereby augments TRAIL-mediated 
apoptosis. Neurosci. Lett., 2009, 453, 92-97.
[206] Banerjee, S.; Li, Y.; Wang, Z.; Sarkar, F.H. Multi-targeted therapy 
of cancer by genistein. Cancer Lett., 2008, 269, 226-242.
[207] Perabo, F.G.E.; Löw, E.C.V.; Rücker, A. V.; Müller, S.C.; Bastian, 
P.J. Soy isoflavone genistein in prevention and treatment of 
prostate cancer. Prostate Cancer P.D., 2008, 11, 6-12.
[208] Li, W.; Frame, L.T.; Hirsh, S.; Cobos, E. Genistein and 
hematological malignancies. Cancer Lett., 2010, 296, 1-8.
[209] Barbara Ann Karmanos Cancer Institute; National Cancer Institute. 
Gemcitabine hydrochloride and genistein in treating women  
with stage IV breast cancer. In: Clinicaltrials.gov [Internet] 2005.
The Role of Phenolic Compounds in the Fight against Cancer – A Review Anti-Cancer Agents in Medicinal Chemistry, 2013, Vol. 13, No. 8    1257 
[Cited 2012 Oct. 30] Available from: http://clinicaltrials.gov/ct2/ 
show/NCT00244933?term=genistein&rank=11 NML Identifier: 
NCT00244933
[210] University of Wisconsin, Madison; National Cancer Institute. 
Genistein in patients who are undergoing surgery for bladder 
cancer. In: Clinicaltrials.gov [Internet] 2005. [Cited 2012 Oct. 30] 
Available from: http://clinicaltrials.gov/ct2/show/NCT00118040? 
term=genistein&rank=17 NML Identifier: NCT00118040
[211] National Cancer Institute; National Institutes of Health Clinical 
Center. A pharmacokinetic study of genistein, a tyrosine kinase 
inhibitor. In: Clinicaltrials.gov [Internet] 1999. [Cited 2012 Oct. 
30] Available from: http://clinicaltrials.gov/ct2/show/NCT00001696? 
term=genistein&rank=21 NML Identifier: NCT00001696
[212] UNC Lineberger Comprehensive Cancer Center; National Cancer 
Institute. Genistein in preventing breast or endometrial cancer in 
healthy postmenopausal women. In: Clinicaltrials.gov [Internet] 
2004. [Cited 2012 Oct. 30] Available from: http://clinicaltrials. 
gov/ct2/show/NCT00099008?term=genistein&rank=25 NML 
Identifier: NCT00099008
[213] Barbara Ann Karmanos Cancer Institute; National Cancer Institute. 
Genistein, Gemcitabine, and Erlotinib in treating patients with 
locally advanced or metastatic pancreatic cancer. In: Clinicaltrials. 
gov [Internet] 2006. [Cited 2012 Oct. 30] Available from: 
http://clinicaltrials.gov/ct2/show/NCT00376948?term=genistein&r
ank=26 NML Identifier: NCT003769
[214] Northwestern University, National Cancer Institute. Genistein in 
treating patients with prostate cancer. In: Clinicaltrials.gov [Internet] 
2010. [Cited 2012 Oct. 30] Available from: http://clinicaltrials. 
gov/ct2/show/NCT01126879?term=genistein&rank=1 NML Identifier: 
NCT01126879
[215] University of Hohenheim; Institute of Nutritional Medicine; 
University Hospital Tübingen; Quercegen Pharmaceuticals LLC. 
Prostate cancer prevention trial with quercetin and genistein 
(QUERGEN). In: Clinicaltrials.gov [Internet] 2012. [Cited 2012 Oct. 
30] Available from: http://clinicaltrials.gov/ct2/show/NCT01538316? 
term=genistein&rank=2 NML Identifier: NCT01538316
[216] Emory University. Study of genistein in reducing side effects of 
superficial bladder cancer treatment. In: Clinicaltrials.gov [Internet] 
2011. [Cited 2012 Oct. 30] Available from: http://clinicaltrials.gov/ 
ct2/show/NCT01489813?term=genistein&rank=7 NML Identifier: 
NCT01489813
[217] Uman Pharma; DSM Nutritional Products, Inc.; MDEIE Ministry, 
Québec Government INRS-Institut Armand Frappier; Université du 
Québec. MTD determination, safety and efficacy of the decitabine-
genistein drug combination in advanced solid tumors and non- 
small cell lung cancer. In: Clinicaltrials.gov [Internet] 2012.
[Cited 2012 Oct. 30] Available from: http://clinicaltrials.gov/ 
ct2/show/NCT01628471?term=genistein&rank=12 NML Identifier: 
NCT01628471 
[218] Northwestern University; National Cancer Institute. Genistein and 
Interleukin-2 in Treating Patients With Metastatic Melanoma  
or Kidney Cancer. In: Clinicaltrials.gov [Internet] 2006. [Cited 
2012 Oct. 30] Available from: http://clinicaltrials.gov/ct2/show/ 
NCT00276835?term=genistein&rank=13 NML Identifier: 
NCT00276835
[219] Choi E.J.; Kim, G. Daidzein causes cell cycle arrest at the G1 and 
G2/M phases in human breast cancer MCF-7 and MDA-MB-453 
cells. Phytomedicine, 2008, 15, 683-690.
[220] Rabiau, N.; Kossaï, M.; Braud, M.; Chalabi, M.; Satih, S.; Bignon 
Y.; Bernard-Gallon, D.J. Genistein and daidzein act on a panel of 
genes implicated in cell cycle and angiogenesis by polymerase 
chain reaction arrays in human prostate cancer cell lines. Cancer 
Epidem., 2010, 34, 200-206.
[221] Guo, J.M.; Xiao, B.X.; Liu, D.H.; Grant, M.; Zhang, S.; Lai, Y.F.; 
Guo, Y.B.; Liu, Q. Biphasic effect of daidzein on cell growth of 
human colon cancer cells. Food Chem. Toxicol., 2004, 42, 1641-
1646.
[222] Liu, X.; Suzuki, N.; Laxmi, Y.R.S.; Okamoto, Y.; Shibutani, S. 
Anti-breast cancer potential of daidzein in rodents. Life Sci., 2012,
91, 415-419.
[223] Constantinou, A.I.; White, B.E.P.; Tonetti, D.; Yang, Y.; Liang, 
W.; Li, W.; Breemen, R.B. The soy isoflavone daidzein improves 
the capacity of tamoxifen to prevent mammary tumours. Eur. J. 
Cancer, 2005, 41, 647-654.
[224] Itoigawa, M.; Ito, C.; Ju-ichi, M.; Nobokuni, T.; Ichiishi, E.; 
Tokuda, H.; Nishino, H.; Furukawa, H. Cancer chemopreventive 
activity of flavanones on Epstein–Barr virus activation and  
two-stage mouse skin carcinogenesis. Cancer Lett., 2002, 176,  
25-29.
[225] Akihisa, T.; Tokuda, H.; Ukiya, M.; Iizuka, M.; Schneider, S.; 
Ogasawara, K.; Mukainaka, T.; Iwatsuki, K.; Suzuki, T.; Nishino, 
H. Chalcones, coumarins, and flavanones from the exudate of 
Angelica keiskei and their chemopreventive effects. Cancer Lett.,
2003, 201, 133-137.
[226] Li, S.; Luo, X.; Li, S.; Dong, M.; Xiong, L. Effect of hesperidin 
extraction on cell proliferation and apoptosis of CNE-2Z cells. 3rd 
International Conference on Biomedical Engineering and 
Informatics, 2010, 2024-2027.
[227] Natarajan, N.; Thamaraiselvan, R.; Lingaiah, H.; Srinivasan, P.; 
Periyasamy, B.M. Effect of flavonone hesperidin on the apoptosis 
of human mammary carcinoma cell line MCF-7. Biomed. Preven. 
Nutr., 2011, 1, 207-215.
[228] Shen, S.; Ko, C.H.; Tseng, S.; Tsai, S.; Chen, Y. Structurally 
related antitumor effects of flavanones in vitro and in vivo:
involvement of caspase 3 activation, p21 gene expression, and 
reactive oxygen species production. Toxicol. Appl. Pharmacol.,
2004, 197, 84-95.
[229] Hsiao, Y.; Hsieh, Y.; Kuo, W.; Chiou, H.; Yang, S.; Chinag, W.; 
Chu, S. The tumor-growth inhibitory activity of flavanone and 2¢-
OH flavanone in vitro and in vivo through induction of cell cycle 
arrest and suppression of cyclins and CDKs. J. Biomed. Sci., 2007,
14, 107-119.
[230] Hafeez, B.B.; Siddiqui, I.A.; Asim, M.; Malik, A.; Afaq, F.; 
Adhami, V.M.; Saleem, M.; Din, M.; Mukhtar, H. A dietary 
anthocyanidin delphinidin induces apoptosis of human prostate 
cancer PC3 cells in vitro and in vivo: involvement of nuclear 
factor-KB signaling. Cancer Res., 2008, 68, 8564-8572.
[231] Hou, D.; Tong, X.; Terahara, N.; Luo, D.; Fujii, M. Delphinidin 3-
sambubioside, a Hibiscus anthocyanin, induces apoptosis in human 
leukemia cells through reactive oxygen species-mediated 
mitochondrial pathway. Arch. Biochem. Biophys., 2005, 440, 101-
109.
[232] Chen, P.; Chu, S.; Chiou, H.; Kuo, W.; Chinag, C.; Hsieh, Y. 
Mulberry anthocyanins, cyanidin 3-rutinoside and cyanidin 3-
glucoside, exhibited an inhibitory effect on the migration and 
invasion of a human lung cancer cell line. Cancer Lett., 2006, 235, 
248-259.
[233] Qian, X.; Li, J.; Ding, J.; Wang, Z.; Duan, L.; Hu, G. 
Glibenclamide exerts an antitumor activity through reactive oxygen 
species–c-jun NH(2)-terminal kinase pathway in human gastric 
cancer cell line MGC-803. Biochem. Pharmacol., 2008, 76, 1705-
1715.
[234] Sun, C.; Zheng, Y.; Chen, Q.; Tang, X.; Jiang, M.; Zhang, J.; Li, 
X.; Chen, K. Purification and antitumour activity of cyanidin-3-O-
glucoside from Chinese bayberry fruit. Food Chem., 2012, 131, 
1287-1294.
[235] Cvorovic, J.; Tramer, F.; Granzotto, M.; Candussio, L.; Decorti, G.; 
Passamonti, S. Oxidative stress-based cytotoxicity of delphinidin 
and cyanidin in colon cancer cells. Arch. Biochem. Biophys., 2010,
501, 151-157.
[236] Ho, M.; Chen, P.; Chu, S.; Kuo, D.; Kuo, W.; Chen J.; Hsieh, Y. 
Peonidin 3-glucoside inhibits lung cancer metastasis by 
downregulation of proteinases activities and MAPK pathway. Nutr. 
Cancer, 2010, 62, 505-516.
[237] Ding, M.; Feng, R.; Wang, S. Y.; Bowman, L.; Lu, Y.; Qian, Y.; 
Castranova, V.; Jiang, B.; Shi, X. Cyanidin-3-glucoside, a natural 
product derived from blackberry, exhibits chemopreventive and 
chemotherapeutic activity. J. Biol. Chem., 2006, 281, 17359-17368.
[238] Littleton, J.; Rogers, T.; Falcone, D. Novel approaches to plant 
drug discovery based on high throughput pharmacological 
screening and genetic manipulation. Life Sci., 2005, 78, 467-475.
[239] Halliwell, B. Free radicals and antioxidants – quo vadis? Trends 
Pharmacol. Sci., 2011, 32, 125-130.
[240] Hollingshead, M.G. Antitumor Efficacy Testing in Rodents. J. 
Natl. Cancer Inst., 2008, 100, 1500-1510.
[241] Pan, L.; Chai, H.; Kinghorn, D. The continuing search for 
antitumor agents from higher plants. Phytochem. Lett., 2010, 3, 1-8.
1258    Anti-Cancer Agents in Medicinal Chemistry, 2013, Vol. 13, No. 8 Carocho and Ferreira 
[242] Ferreira, I.C.F.R.; Vaz, J.A.; Vasconcelos, M.H.; Martins, A. 
Compounds from wild mushrooms with antitumor potential. Anti-
Cancer Agents Med. Chem., 2010, 10, 424-436.
[243] Boopathy, N.S.; Kathiresan, K. Anticancer drugs from marine 
flora: an overview. J. Oncol., 2010, 1-18.
Received: December 09, 2012 Revised: February 07, 2013 Accepted: June 09, 2013 
